,Name_VH,Name_VL,Genbank_protein_id_vh,Genbank_protein_id_vl,Binds_to,Origin,VH,VL,Reference,Description_VH,Description_VL,Date_added
0,D27,D27,7VYR_A,7VYR_B,SARS-CoV-2,Homo sapiens (human),mewswvflfflsvttgvlsqvqlqqsgaevkkpgssvkvsckasggtfgnwsiswvrqapgqglewmggidpsrgeatyaqkfqgrvtittdeststaymelsslrsedtavyycareteqggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthhhhhhhhh,mgikmethsqvfvymllwlsgvegsyeltqppsvsvapgktaritcggnnigrksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvydlfsdyvfgtgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Jeong,B.S. et al.; Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants; MAbs 14 (1), 2021601 (2022); 2022.","Chain A, D27 heavy chain","Chain B, D27 light chain",2022-03-14
2,S3H3,S3H3,7WK9_a,7WK9_b,SARS-CoV-2,Mus musculus (house mouse),qvqlqqpgaelvrpgasvklsckasgysftrfwmnwvkqrpgqglewigmihpsdsetrlnqkfkdkatltvdkssttaymqlssptsedsavyycarkdydydawfaywgqgtlvtvsaakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,divltqspaslavslgqratiscrasksvsasvysymhwyqqkpgqppklliylasslesgvparfsgsgsgtdftlnihpveeedaatyychhsrelppafgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnr,"Hong,Q. et al.; Structural basis for ACE2 engagement and antibody evasion and neutralization of SARS-CoV-2 Omicron variant; Unpublished; 2022.","Chain a, Heavy chain of S3H3 Fab","Chain b, Light chain of S3H3 Fab",2022-03-14
7,DH1042,DH1042,7THT_d,7THT_b,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaylelsslrsedtavyycarymvtrdqyyydmdvwgqgttvtvs,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysppptfgqgtklei,"Gobeil,S.M. et al.; Structural diversity of the SARS-CoV-2 Omicron spike; bioRxiv (2022); 2022.","Chain d, DH1042 heavy chain","Chain b, DH1042 light chain",2022-03-14
10,DH1058,DH1058,7TOW_A,7TOW_B,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgfnfgdfgmhwvrqapgkglewvavisyegrnknhadsvrgrftisrdnsrnmlylqmnslrrgdtavyycakenrdrnydswsasysdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspsflsasvgdrvtitcrasqgidrylawyqqkpgsapklliyaastlqsgvpsrfsgsgsetdftltisslqpddfatyycqqlstyptitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Gobeil,S.M. et al.; Structural diversity of the SARS-CoV-2 Omicron spike; bioRxiv (2022); 2022.","Chain A, DH1058 Fab heavy chain","Chain B, DH1058 Fab Light chain",2022-03-14
12,S304,S304,7TN0_M,7TN0_N,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.","Chain M, S304 Fab heavy chain","Chain N, S304 Fab light chain",2022-03-14
14,S309,S309,7TN0_C,7TN0_D,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.","Chain C, S309 heavy chain","Chain D, S309 light chain",2022-03-14
16,S309,S309,7TM0_N,7TM0_O,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,ivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkve,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.","Chain N, S309 Fab Heavy Chain","Chain O, S309 Fab light chain",2022-03-14
19,S2L20,S2L20,7TM0_I,7TM0_H,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfnsygmhwvrqapgkglewvafirydggnkyyadsvkgrftisrdnskntlylqmkslraedtavyycanlkdsrysgsyydywgqgtlvtvss,viwmtqspsslsasvgdrvtitcqasqdirfylnwyqqkpgkapkllisdasnmetgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpftfgpgtkvdfk,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.","Chain I, S2L20 Fab heavy chain","Chain H, S2L20 Fab light chain",2022-03-14
23,S309,S309,7TLY_A,7TLY_B,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvs,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.","Chain A, S309 Fab heavy chain","Chain B, S309 Fab light chain",2022-03-14
24,A5-10,A5-10,7F7E_C,7F7E_L,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaivgsggstyyadsvkgrfiisrdnskntlylqmnslraedtavyycaksliyghydiltgayyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,aqmtqspssvsasvgdrvtipcrasqgignwlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfppfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtk,"Wang,F. et al.; Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants; Emerg Microbes Infect 11 (1), 548-551 (2022); 2022.","Chain C, Heavy chain of A5-10 Fab","Chain L, Light chain of A5-10 Fab",2022-03-14
25,P36-5D2,P36-5D2,7FAF_g,7FAF_f,SARS-CoV-2,Homo sapiens (human),mgwsciilflvatatgvhsqvqlvqsgaevkkpgasvkvsckasgytfttyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyycaggggrrlqfdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,mgwsciilflvatatgvhsdiqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyngypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Shan,S. et al.; A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants; Front Immunol 12, 766821 (2021); 2021.","Chain g, P36-5D2 heavy chain","Chain f, P36-5D2 light chain",2022-03-14
31,CV503,CV503,7LQ7_H,7LQ7_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgiswvrqapgqglewmgriipilgtanhaqkfqgrvtitadkstgtvymelsslrsedtavyycardgdsgsyyetlgfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","Chain H, CV503 heavy chain","Chain L, CV503 light chain",2022-03-14
32,COVA1-16,COVA1-16,7LQ7_y,7LQ7_z,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","Chain y, COVA1-16 heavy chain","Chain z, COVA1-16 light chain",2022-03-14
37,NT-193,NT-193,7E5O_H,7E5O_L,SARS-CoV-2,Homo sapiens (human),evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargwdldyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkgsslevlfqgplghhhhhh,airmtqspsamsasvgdrvtvtcrasqgignylawfqlkpgkvpkrliyaasslqsgvparfsgggsgteftltisslqpedfatyyclqhgflpwtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Onodera,T. et al.; A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site; Immunity 54 (10), 2385-2398 (2021); 2021.","Chain H, NT-193 Heavy chain","Chain L, NT-193 Light chain",2022-03-14
38,RBD-CHAB45,RBD-CHAB45,7F63_H,7F63_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlqqsgpelvkpgasvkiscktsgytfteytiywvkqslgkslewiggnnpnnddttykqffkgkatltvdkssstaymelrsltsedsavyycardgypyyyaldfwgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,divmtqsqkfmstsvgdrvsvtckssqnvgtnvawyqqkpgqspkaliysasyrysgvpdhftgsgsgtdftltisnvqsadlaeyfcqqynnypwtfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Su,S.C. et al.; Structure-guided antibody cocktail for prevention and treatment of COVID-19; PLoS Pathog 17 (10), e1009704 (2021); 2021.","Chain H, RBD-chAb45, Heavy chain","Chain L, RBD-chAb45, Light chain",2022-03-14
39,RBD-CHAB-25,RBD-CHAB-25,7F62_H,7F62_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqleesggglvkpggslklscaasgftfssytmswvrqspekrlewvaeissggtytnypdtatgrftisrdnakntlylemsslrsedtamyycanfgnyeeiaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,qivltqspaimsvslgervtmtctasssvsssylhwyqqkpgsspklwiystsnlasgvparfsgsgsgtsysltissmeaedaatyychqyhrspytfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Su,S.C. et al.; Structure-guided antibody cocktail for prevention and treatment of COVID-19; PLoS Pathog 17 (10), e1009704 (2021); 2021.","Chain H, RBD-chAb-25, Heavy chain","Chain L, RBD-chAb-25, Light chain",2022-03-14
40,HB27,HB27,7CYP_I,7CYP_H,SARS-CoV-2,Homo sapiens (human),vklvesggglvkpggslrlscaasgftftnygmswvrqapgkrlewvaeissggsytyypdtvtgrftisrdnakntlylqmnslraedtavyycarfryggggtvdywgqgtlvtvss,ivltqsptlslspgeratlscrasesvdnygisfmnwfqqkpgqaprlliyaasnqgsgipsrfsgsgsgtdfsltisslepedfavyfcqqskevprifgqgtkveilk,"Zhu,L. et al.; Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2; Natl Sci Rev 8 (3), nwaa297 (2020); 2021.","Chain I, Heavy chain of HB27","Chain H, Light chain of HB27",2022-03-14
43,FC08,FC08,7DX4_H,7DX4_L,SARS-CoV-2,Homo sapiens (human),qllqqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipiigianyaqkfqgrvtitadkststaymelsslrsedtavyycarergysgygaayyfdywgqgtlvtvssa,svltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvlgq,"Zhang,L. et al.; A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2; Natl Sci Rev 8 (8), nwab053 (2021); 2021.","Chain H, Heavy chain of FC08 Fab","Chain L, Light chain of FC08 Fab",2022-03-14
44,FC05,FC05,7D4G_N,7D4G_G,SARS-CoV-2,Homo sapiens (human),evqlleqsgaevkkpgasvrvsckvsgytlpevamhwvrqapgkglewmggfdpedgetmyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatttpfsssywfdpwgqgtlvtvss,qsvltqapsvsgapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,"Zhang,L. et al.; A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2; Natl Sci Rev 8 (8), nwab053 (2021); 2021.","Chain N, Heavy chain of FC05 Fab","Chain G, Light chain of FC05 Fab",2022-03-14
45,COVA2-39,COVA2-39,7JMP_H,7JMP_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviytggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarahvdtamvesgafdiwgqgtrvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wu,N.C. et al.; An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain; Cell Rep 33 (3), 108274 (2020); 2020.","Chain H, COVA2-39 heavy chain","Chain L, COVA2-39 light chain",2022-03-14
46,COVA2-04,COVA2-04,7JMO_H,7JMO_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardleraggmdvwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygslytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wu,N.C. et al.; An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain; Cell Rep 33 (3), 108274 (2020); 2020.","Chain H, COVA2-04 heavy chain","Chain L, COVA2-04 light chain",2022-03-14
47,K398.22,K398.22,7TP4_H,7TP4_L,SARS-CoV,Macaca mulatta (Rhesus monkey),evqlaesggglvkpggslrlscvasgftfssnemhwvrqapgkglewvsvisesgftteyadsvkgrftisrdnaknslflqmnslraedtavyyctrvsifgqfivatyfdywgqgvlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qaaltqprsvsgspgqsvtisctgtssdiggynyvswyqqhpgtapklmiyavserpsgvsdrfsgsksgntasltisglqaedeadyyccsyagtvlfgggtrltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"He,W. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Unpublished; 2022.","Chain H, K398.22 heavy chain","Chain L, K398.22 light chain",2022-03-14
48,K288.2,K288.2,7TP3_H,7TP3_L,SARS-CoV,Macaca mulatta (Rhesus monkey),evrlvesggglvkpggslrlscvasgftfssyemhwvrqapgkglewvsvisesgatthytdsvkgrftisrdnaknslflqmnslraedtavyyctrpqsvtvfgvaatsyeafdfwgqglrvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,divmtqspdtlslspgetatlscrasqsvssyvawyqqkpeqpprlliygsssratgmpdrfsgsgsgtdftltisslepddfavyycqqytnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"He,W. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Unpublished; 2022.","Chain H, K288.2 heavy chain","Chain L, K288.2 light chain",2022-03-14
49,FI3A,FI3A,7Q0A_Y,7Q0A_Z,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvs,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdik,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.","Chain Y, FI3A fab heavy chain","Chain Z, FI3A fab Light chain",2022-03-14
50,FD-5D,FD-5D,7PR0_G,7PR0_F,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycaspggitaagtsvlfgyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpitwtfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.","Chain G, FD-5D Fab heavy chain","Chain F, FD-5D Fab light chain",2022-03-14
53,FD-11A,FD-11A,7PQZ_A,7PQZ_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgpdiltgyynyyyygmdvwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgfyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.","Chain A, FD-11A Fab heavy chain","Chain B, FD-11A Fab light chain",2022-03-14
54,FI-3A,FI-3A,7PQZ_H,7PQZ_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.","Chain H, FI-3A Fab heavy chain","Chain L, FI-3A Fab light chain",2022-03-14
57,S2K146,S2K146,7TAT_F,7TAT_G,not determined,Homo sapiens (human),qvqlvesggvvvqpggslrlscaasgftfhdhtmhwvrqapgkglewvslitwnggtihysdsvkgrftisrdnsknslylqmnslrtedtalyycakdlgrggwylpsdawgqgtlvtvss,qsvltqppsasgtpgqrvtiscsgssanigsntvnwyqhlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslkgvfgggtkltvl,"Park,Y.J. et al.; Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry; Science 375 (6579), 449-454 (2022); 2022.","Chain F, S2K146 Fab heavy chain","Chain G, S2K146 Fab light chain",2022-03-14
61,DH1047,DH1047,7SG4_H,7SG4_L,not determined,Homo sapiens (human),qvqlvqsgaevkkpgasvqvscqasantftnhyihwvrqapgqglewmgiiyptggntiyaqgfqgrvtmtrdtslntiylelsslrsedtavyycardvrvddswsgydllsggtyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,divmtqspdslavslgeratincrssqsvlyssnnenylawyqqkpgqppklliywastresgipdrfsgsgsgtdftltisrlqaedvavyycqqyyslprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Martinez,D.R. et al.; A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice; Sci Transl Med 14 (629), eabj7125 (2022); 2021.","Chain H, DH1047 Heavy chain","Chain L, DH1047 light chain",2022-03-14
62,CV38-142,CV38-142,7LM9_H,7LM9_L,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkiscqgsgysftsywigwvrqmpgkglewmgiiypgesdtrysssfqghvtisadksistaylqwsslkasdtamyycarirgvyssgwiggdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprqwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Liu,H. et al.; A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection; bioRxiv (2021); 2021.","Chain H, CV38-142 Fab heavy chain","Chain L, CV38-142 Fab light chain",2022-03-14
64,COVA1-16,COVA1-16,7LM8_H,7LM8_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Liu,H. et al.; A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection; bioRxiv (2021); 2021.","Chain H, COVA1-16 Fab heavy chain","Chain L, COVA1-16 Fab light chain",2022-03-14
65,COVA1-16,COVA1-16,7JMX_H,7JMX_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,H. et al.; Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity; bioRxiv (2020); 2020.","Chain H, COVA1-16 heavy chain","Chain L, COVA1-16 light chain",2022-03-14
67,AB-3467,AB-3467,7MSQ_H,7MSQ_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyhwnwirqppgkglewigyiyysgntnynpslksrvsistdtsknqfslklssvtaadtavyycvremrrgysgydywdlyafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyphtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Burnett,D.L. et al.; Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability; Immunity 54 (12), 2908-2921 (2021); 2022.","Chain H, AB-3467 Fab Heavy Chain","Chain L, AB-3467 Fab Light Chain",2022-03-14
69,BETA-43,BETA-43,7Q0I_A,7Q0I_B,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnnfyadsvkgrftisrdnfkntlylqmnslraedtavyycarsycsggfcfgyyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvapgktatitcggnnigtksvhwyqqkpgqapvlviyynsdrpsgiperfsgsnsgntvtltisrveagdeadyycqvwdsgsdhyvfgtgtkvtvvgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain A, Beta-43 heavy chain","Chain B, Beta-43 Fab light chain",2022-03-14
71,BETA-50,BETA-50,7Q0H_A,7Q0H_B,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasrgtfntyvftwvrqapgqglewmggiipffgtadyaqkfqgrvtitaddststaymelsslrsedtavyycsrlsqwdllpmwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspgtlslspgeratlscrasqsftssylawyqqkpgqaprlliygassratgipdrfsgtgsgtdftltisrlepedfavyycqqygtsprmytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain A, Beta-50 Fab heavy chain","Chain B, Beta-50 Fab light chain",2022-03-14
72,BETA-54,BETA-54,7Q0H_H,7Q0H_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvfggsitssnhywvwirqppgkglewigsmyysgstaynpsltnrvtisvdtsknqfslklssvtaadtavyycarqigpkrpsqvadwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain H, Beta-54 Fab heavy chain","Chain L, Beta-54 Fab light chain",2022-03-14
73,BETA-49,BETA-49,7Q0G_A,7Q0G_B,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfsssviswvrqapgqglewmggiiplfgsanyaqkfqgrvtitadeststaymemtslrsedtavyycakvsqwalilfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspswtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain A, Beta-49 Fab heavy chain","Chain B, Beta-49 Fab light chain",2022-03-14
74,FI-3A,FI-3A,7Q0G_H,7Q0G_L,SARS-CoV-2,Homo sapiens (human),evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain H, FI-3A Fab heavy chain","Chain L, FI-3A Fab light chain",2022-03-14
75,BETA-06,BETA-06,7Q9P_J,7Q9P_K,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisssshywgwirqppgkglewigsiyysesayynpslksrvtmsidtsknqfslklnsvtaadtavyycarvteprwtscyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivmtqspatlslspgeratlscrtsqsvtsylawyqqrpgqaprlliydasdratgiparfsgsgsgtdftltisnlepedfavyycqlrsnwppitfgqgtrletkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain J, Beta-06 heavy chain","Chain K, Beta-06 light chain",2022-03-14
78,BETA-53,BETA-53,7Q9M_E,7Q9M_F,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgeslrisckgsghnspsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslqasdtaiyycarhvvalthlypdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspatlsvspgeratlscrasqsvsstlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwstwtfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain E, Beta-53 fab heavy chain","Chain F, Beta-53 fab light chain",2022-03-14
81,BETA-32,BETA-32,7Q9K_D,7Q9K_E,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittgymelsslrsddtalyycarvgahdyydssdnwfdpwgqgtlvtvfsastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspssvsasvgdrltitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain D, Beta-32 heavy chain","Chain E, Beta-32 light chain",2022-03-14
83,BETA-26,BETA-26,7Q9J_J,7Q9J_K,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsgasisnyywswirqppgkglewvgyiyytgstnhnpslksrvtisldtsknqfslrlssvtaadtavyycaraycsggscfdtfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvapgqtaritcggnnigsksvhwfqqkpgqapvlvvyddsdrpsgiperfsgsnsgntasltisrveagdeadyycqvwdsasdsgvfgtgtkltvpgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain J, Beta-26 heavy chain","Chain K, Beta-26 light chain",2022-03-14
89,COVOX-222,COVOX-222,7Q9G_E,7Q9G_F,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycargegspgnwfdpwgqgtlvtvss,dvvmtqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqhydtsprfgggtkvdik,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain E, COVOX-222 heavy chain","Chain F, COVOX-222 light chain",2022-03-14
94,BETA-40,BETA-40,7PS7_H,7PS7_B,SARS-CoV-2,Homo sapiens (human),qvqlvesgpgqvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgsayynpslksrvtisvdtsknqfslklnsvtaadtavfycarhaapspgdnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qsvltqppsvsvspgqtaritcsgdalstqngnwyqqkpgqapvmvickdserpsgiperfsgsrsgttvtltisgvqaedeadyhcqsadnrahvvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain H, Beta-40 heavy chain","Chain B, Beta-40 Fab light chain",2022-03-14
96,BETA-44,BETA-44,7PS6_C,7PS6_D,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwispyngnthyaqklqgrvtmttdtststaymelrslrsddtavyycardgellgwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvvtqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyagskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecsec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain C, Beta-44 Fab heavy chain","Chain D, Beta-44 Fab light chain",2022-03-14
98,BETA-47,BETA-47,7PS5_H,7PS5_L,SARS-CoV-2,Homo sapiens (human),qvqlvesgpemkkpgtsvkvsckasgftfitsavqwvrqargqrlewmgwiavgsgntnyaqkfqdrvtinrdmststaymelsslrsedtavyycaaphcnrtschdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqsvsrnylawyqqkpgqvprlliygassratgipdrfrgsgsgtdftltinrlesedfavyycqqygsslftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain H, Beta-47 Fab heavy chain","Chain L, Beta-47 Fab light chain",2022-03-14
99,BETA-38,BETA-38,7PS4_B,7PS4_C,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnywigwvrqmpgkglewmgiiypgdsgtryspsfqgqvtisadksirtaylqwsslkasdsamyycarsrvgatggyydyymdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qsvltqppsasgtpgqrvtiscsgsssnlggntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain B, Beta-38 Fab heavy chain","Chain C, Beta-38 Fab light chain",2022-03-14
102,BETA-29,BETA-29,7PS2_A,7PS2_B,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygmhrvrqapgkglewvalisyeesnryygdsvrgrftisrdnskntlylqmnslrpedtavyycakdqgpatvmvtairgamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyfgspsitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain A, Beta-29 Fab heavy chain","Chain B, Beta-29 Fab light chain",2022-03-14
103,BETA-27,BETA-27,7PS1_A,7PS1_B,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgltvrsnymnwvrqapgkglewvsliysggstfyadsvkgrftisrhdskntlylqmnslraedtavyycardlvvygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgeratlscrasqsvsssslawyqqkhgqaprlliygtssratgipdrfsgsgsgtdftltisglepedfavyycqqygssplfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain A, Beta-27 Fab heavy chain","Chain B, Beta-27 Fab light chain",2022-03-14
104,BETA-24,BETA-24,7PS0_B,7PS0_C,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpglvkpsqtlsltcsvsdgsisssdyywswirqppgkglewigyiyytgstyynpslksrvsisvdrsknqfslklssvtaadtavyycarlvvpspkgswfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqpasvsgspgqsitisctgtsidvgnynlaswyqqhpgkapkliiyegsrrpsgvsnrfsgaksgntasltisglqaedeadyyccsyvgsstyvfgsgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain B, Beta-24 heavy chain","Chain C, Beta-24 light chain",2022-03-14
106,BETA-22,BETA-22,7PRZ_H,7PRZ_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygihwvrqapgkglewvavisydgshkyyadsvkgrftisrdnskntlylqmnslktedtavyycakdssaaipyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,aiqmtqspdslavslgeratinckssqsilynsnnktylawyqqkpgqppkllifwastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiplifgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain H, Beta-22 Fab heavy chain","Chain L, Beta-22 Fab light chain",2022-03-14
107,BETA-6,BETA-6,7PRY_C,7PRY_D,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisssshywgwirqppgkglewigsiyysesayynpslksrvtmsidtsknqfslklnsvtaadtavyycarvteprwtscyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivmtqspatlslspgeratlscrtsqsvtsylawyqqrpgqaprlliydasdratgiparfsgsgsgtdftltisnlepedfavyycqlrsnwppitfgqgtrletkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain C, Beta-6 Fab heavy chain","Chain D, Beta-6 Fab light chain",2022-03-14
108,COVOX-45,COVOX-45,7PRY_F,7PRY_G,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggsyayyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftitslqpediatyycqqydnlpltfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","Chain F, COVOX-45 Fab heavy chain","Chain G, COVOX-45 Fab light chain",2022-03-14
112,BETA-49,BETA-49,7Q6E_J,7Q6E_K,not determined,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfsssviswvrqapgqglewmggiiplfgsanyaqkfqgrvtitadeststaymemtslrsedtavyycakvsqwalilfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspswtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Afonine,P.V. et al.; Real-space refinement in PHENIX for cryo-EM and crystallography; Acta Crystallogr., Sect. D: Biol. Crystallogr. 74, 531 (2018); 2021.","Chain J, Beta-49 heavy chain","Chain K, Beta-49 light chain",2022-03-14
115,CV3-25,CV3-25,7NAB_A,7NAB_B,SARS-CoV,Homo sapiens (human),evqlvesgaevkkpgeslkisckgsgytftrywigwvrqmpgkglewmgiiypgdsdtryspsfqghvtisadksistaylqwnslkasdtamyycarlpqycsngvcqrwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,eivltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpytfgqgtnleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Zhou,P. et al.; A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes; bioRxiv (2021); 2021.","Chain A, CV3-25 Fab Heavy Chain","Chain B, CV3-25 Fab Light Chain",2022-03-14
117,LY-COV1404,LY-COV1404,7MMO_D,7MMO_E,SARS-CoV-2,Homo sapiens (human),xitlkesgptlvkptqtltltctfsgfslsisgvgvgwlrqppgkalewlaliywdddkryspslksrltiskdtsknqvvlkmtnidpvdtatyycahhsistifdhwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,qsaltqpasvsgspgqsitisctatssdvgdynyvswyqqhpgkapklmifevsdrpsgisnrfsgsksgntasltisglqaedeadyycssyttssavfgggtkltvlgrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Westendorf,K. et al.; LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants; bioRxiv (2022); 2021.","Chain D, LY-CoV1404 Fab heavy chain","Chain E, LY-CoV1404 Fab light chain",2022-03-14
119,MW07,MW07,7DK2_J,7DK2_K,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdasekyyldslkgrftisrdnaknslylqmnslraedtavyycardlgilwfgdypwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsasvgdrvtitcrasqgisnslawyqqkpgkapklllyaastlesgvpsrfsgsgsgtdftltisslqpedfatyycqqfystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Sun,Y. et al.; Architectural versatility of spike neutralization by a SARS-CoV-2 antibody; Unpublished; 2021.","Chain J, MW07 heavy chain","Chain K, MW07 light chain",2022-03-14
123,WRAIR-2151,WRAIR-2151,7N4M_H,7N4M_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgprlvkpsetlsltctvsggsisgsnyfwgwirqppgkglewigtiyyggstyynpslksrvtisvdtsenqfslklssvtaadtavyycanlawlrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsvsltisglktedeadyycqsydssnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.","Chain H, WRAIR-2151 antibody Fab heavy chain","Chain L, WRAIR-2151 antibody Fab light chain",2022-03-14
124,WRAIR-2125,WRAIR-2125,7N4L_H,7N4L_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlslqmnslrpedtavyycakdspyyydssgyypgyfqdwgqgslvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasigdrvtitcrasqtisdylnwyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.","Chain H, WRAIR-2125 antibody Fab heavy chain","Chain L, WRAIR-2125 antibody Fab light chain",2022-03-14
125,WRAIR-2173,WRAIR-2173,7N4J_H,7N4J_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsgdsisssdyswgwirqppgkglewigtiyyikntyynpslrsrvtlsvdtsknlfslklssvtaadtavyycarerppfdvvvvpaarpynwfdpwglgtlvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvlmqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaddeadyycqsydsslsgskvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.","Chain H, WRAIR-2173 antibody Fab heavy chain","Chain L, WRAIR-2173 antibody Fab light chain",2022-03-14
126,WRAIR-2057,WRAIR-2057,7N4I_H,7N4I_L,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfisywiawvrqmpgkglewmgiiypgdsdttyspsfqgqvtisadksistaylqwsslkasdtaiyycarllyysdsspldswgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqshstprtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.","Chain H, WRAIR-2057 Antibody Fab Heavy Chain","Chain L, WRAIR-2057 Antibody Fab Light Chain",2022-03-14
127,P22A-1D1,P22A-1D1,7CHS_H,7CHS_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrdyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyyclhlnsyrtfglgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.","Chain H, antibody P22A-1D1 heavy chain","Chain L, antibody P22A-1D1 light chain",2022-03-14
128,P5A-3C8,P5A-3C8,7CHP_H,7CHP_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsfiysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlqehgmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkke,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqhlnsyppgytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.","Chain H, antibody P5A-3C8 heavy chain","Chain L, antibody P5A-3C8 light chain",2022-03-14
129,P5A-1D2,P5A-1D2,7CHO_B,7CHO_C,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsiiysggstyyadsvkgrftisrdnsnntlylqmnslraedtavyycaralqvgatsdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedetdyycqscdsslsvvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.","Chain B, antibody P5A-1D2 heavy chain","Chain C, antibody P5A-1D2 light chain",2022-03-14
131,SARS2-38,SARS2-38,7MKL_H,7MKL_L,SARS-CoV-2,Mus musculus (house mouse),qvqlkesgpglvapsqslsitctvsgfsltrygvhwvrqppgkglewlgviwadgstyynsalmsrlsiskdnsksqvflnmnslqtddtakyycardgrgyddywgqgttlt,qivltqspaimsaspgekvtmtcsasstvsfiywyqqkpgssprlliydtsnpasgvpvrfsgsgcgtsyyltisrmeaedaatyycqqwntypltfgagtklel,"VanBlargan,L. et al.; A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope; bioRxiv (2021); 2021.","Chain H, SARS2-38 Fv heavy chain","Chain L, SARS2-38 Fv light chain",2022-03-14
133,P2C-1A3,P2C-1A3,7CDJ_H,7CDJ_L,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardfshqqlvpswgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ge,J. et al.; Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry; Nat Commun 12 (1), 250 (2021); 2020.","Chain H, antibody P2C-1A3 heavy chain","Chain L, antibody P2C-1A3 light chain",2022-03-14
134,P2C-1F11,P2C-1F11,7CDI_H,7CDI_L,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyhcardlvvygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ge,J. et al.; Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry; Nat Commun 12 (1), 250 (2021); 2020.","Chain H, antibody P2C-1F11 heavy chain","Chain L, antibody P2C-1F11 light chain",2022-03-14
135,EY6A,EY6A,6ZDG_F,6ZDG_G,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfssydmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggklwvyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhou,D. et al.; Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient; Nat Struct Mol Biol 27 (10), 950-958 (2020); 2020.","Chain F, EY6A heavy chain","Chain G, EY6A light chain",2022-03-14
147,2-36,2-36,7N5H_J,7N5H_K,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvsssnyywswirqppgkglewigymyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycarevyyydrsgyyasdgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkveik,"Wang,P. et al.; A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses; bioRxiv (2021); 2021.","Chain J, 2-36 Fab heavy chain","Chain K, 2-36 Fab light chain",2022-03-14
150,7D6,7D6,7EAM_C,7EAM_D,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgaelvrpgasvklsctasgfnikdtyihwvkqrpeqglewigridpgdgdteydpsfqgkatitadtssntaylelssltsedtavyyctrfydyvdygmdywgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkiepr,diqmtqspaslsasvgetvtitcrasgnihnylawyqqkqgkspqllvynaktladgvpsrfsgsgsgtqyslkinslqpedfgsyycqhfwstppwtfgggtklevkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnn,"Li,T. et al.; Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants; Nat Commun 12 (1), 5652 (2021); 2021.","Chain C, the heavy chain of Fab fragment of antibody 7D6","Chain D, the light chain of Fab fragment of antibody 7D6",2022-03-14
152,6D6,6D6,7EAN_H,7EAN_L,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgaelvkpgasvklscttsgfniidtymhwvkqrpeeglewiggidpvngnseydpkfqdkatitadtssntaylhlsrltsedtavyycasahyygssssfpywgqgtdlvtvsakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsspwpsetvtcnvahpasstkvdkkivprg,divmtqsqkfmstsvgdrvsvtckasqnvgthvawyqqkpgqspkaliysasyrysgvpdrftgsgvgtdftltitnvqsedlaeyfcqqynsyftfgsgtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnr,"Li,T. et al.; Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants; Nat Commun 12 (1), 5652 (2021); 2021.","Chain H, Heavy chain of SARS-CoV-2 cross-neutralizing mAb 6D6","Chain L, Light chain of SARS-CoV-2 cross-neutralizing mAb 6D6",2022-03-14
153,XG014,XG014,7V2A_I,7V2A_H,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfsnywigwvrhmpgkglewmgiiypgdsdtryspsfqgqvtisvdtsistaylqwsslkasdtamyyctrhqygynygyfyyyidvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsvltqppsvsaapgqkvtiscsgsssnignnpvswyrqvpgtapklliydnnkrpsgipdrfsgsksgasatlgitglqtgdeadyycgtwhtslssgvfgggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,Z. et al.; An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope; Protein Cell (2021) In press; 2021.","Chain I, The heavy chain of XG014","Chain H, The light chain of XG014 Fab",2022-03-14
156,XG005,XG005,7V26_e,7V26_f,SARS-CoV,Homo sapiens (human),qvtlresgptlvkpkqtltltctfsgfslstpgggvgwirqppgkalewlaliywdddkryspslkssltitkdtsknqvvltmtnmdpvdtatyycarltaadtifdcwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspglsitisctatssdvgaynyvswyqqhpgqapklmiydvskrpsgvsnrfsgsksantasltisglqaedeadyycssytttsvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,Z. et al.; An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope; Protein Cell (2021) In press; 2021.","Chain e, XG005 Heavy chain","Chain f, XG005 Light Chain",2022-03-14
159,P5C3,P5C3,7P40_I,7P40_H,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqqfqervtitrdmststaymelsslgsedtavyycaapncsggscydgfdlwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,eivltqspgtlslspgeratlscrgsqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikgtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Fenwick,C. et al.; A highly potent antibody effective against SARS-CoV-2 variants of concern; Cell Rep 37 (2), 109814 (2021); 2021.","Chain I, Variable Heavy Chain P5C3 (VH)","Chain H, Variable Light Chain P5C3 (VL)",2022-03-14
162,GH12-FAB,GH12-FAB,7D6I_B,7D6I_C,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyyctragwvrgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkththhhhhhhh,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnlwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Shi,R. et al.; A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2; Unpublished; 2021.","Chain B, Heavy chain of GH12-Fab","Chain C, Light chain of GH12-Fab",2022-03-14
163,N-612-004,N-612-004,7S0E_H,7S0E_L,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyymhwvrqapgkglewvsaisgsggytyyadsvkgrftisrdnskntlylqmnslraedtavyycardrdhaydwgfdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqwadwpltfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.","Chain H, N-612-004 Fab heavy chain","Chain L, N-612-004 Light Chain",2022-03-14
164,N-612-014,N-612-014,7S0D_O,7S0D_P,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamtwvrqapgkglewvsyisgsgggtyyadsvkgrftisrdnskntlylqmnslraedtavyycardrwasgwlafdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqayaypltfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.","Chain O, N-612-014 Fab Heavy Chain","Chain P, N-612-014 Light Chain",2022-03-14
167,N-612-017,N-612-017,7S0C_M,7S0C_N,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaiwgsgsntyyadsvkgrftisrdnskntlylqmnslraedtavyycargrdlaaftktafdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqhdalpwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.","Chain M, N-612-017 Fab Heavy Chain","Chain N, N-612-017 Light Chain",2022-03-14
169,N-612-056,N-612-056,7S0B_C,7S0B_D,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvslisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlwgsgffafdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqdagtpltfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.","Chain C, N-612-056 Fab Heavy Chain","Chain D, N-612-056 Light Chain",2022-03-14
171,FAB_8D3_2,FAB_8D3_2,7RXD_H,7RXD_L,not determined,Mus musculus (house mouse),dvqlvesggglvqpgkslrlscaasgftfsnfgmhwvrqapemglewvayissgsttkyygdtvkgrftisrdnpkntlylqmnslrsedtamyycarrplydgdygypmdywgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,nimltqspsslavsagervtmsckstqsilynsnqktylawyqqkpgqspklliywastrasgvpdrftgsgsgtdftltinsvqpedlavyychqylsawtfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wu,X. et al.; Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies); Proc Natl Acad Sci U S A 118 (41) (2021); 2021.","Chain H, Fab_8D3_2 heavy chain","Chain L, Fab_8D3_2 light chain",2022-03-14
173,8D3,8D3,7R9D_H,7R9D_L,not determined,Mus musculus (house mouse),dvqlvesggglvqpggsrklscaasgftfsnfgmhwvrqapemglewvayissgsttiyygdtvkgrftisrdnpkntlflqmtslrsedtamyycarrplydgdygypmdywgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgs,nimltqspsslavsagervtmsckstqsilynsnqktylawyqqkpgqspklliywastrasgvpdrftgsgsgtdftltinsvqpedlavyychqylsawtfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wu,X. et al.; Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies); Proc Natl Acad Sci U S A 118 (41) (2021); 2021.","Chain H, Fab 8D3 heavy chain","Chain L, Fab 8D3 light chain",2022-03-14
174,2H04,2H04,7K9K_H,7K9K_L,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),evqlqqsgaelvkpgasvkmsckasgytftsywitwvkqrpgqglewigdiypgsgstkynekfrseatltvdtssttaymqlssltsedsavyycarwdfygsrtfdywgqgttltvssa,divltqspailsvspgervsfscrasqnigtiihwyqqrtngsprllikyasesvsgipsrfsgsgsgtdftlsinsvesediadyycqqssswpltfgagtklel,"Errico,J.M. et al.; Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD; Cell Rep 37 (4), 109881 (2021); 2021.","Chain H, 2H04 heavy chain","Chain L, 2H04 light chain",2022-03-14
178,2B04,2B04,7K9I_H,7K9I_L,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),qvqlkqsgpglvapsqslsitctvsgfslinyaiswvrqppgkglewlgviwtgggtnynsalksrlsiskdnsksqvflkmnslqtddtaryycarkdyygryygmdywgqgtsvtvs,qavvtqesalttspgetvtltcrsstgavttsnyanwvqekpdhlftgliggtnnrapgvparfsgsligdkaaltitgaqtedeaiyfcalwynnhwvfgggtkltvl,"Errico,J.M. et al.; Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD; Cell Rep 37 (4), 109881 (2021); 2021.","Chain H, 2B04 heavy chain","Chain L, 2B04 light chain",2022-03-14
181,COV11,COV11,7S4S_H,7S4S_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlevagaidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqsisssylawyqqkpgqaprlliygatsratgtpdrfsgsgsgtdftltinrlepedfavyycqqygsspgytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdsrdstyslgstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tolbert,W.D. et al.; Crystal Structure of SARS-CoV-2 S receptor-binding domain (RBD) in complex CoV11 Fab; Unpublished; 2021.","Chain H, CoV11 heavy chain","Chain L, CoV11 light chain",2022-03-14
182,C118,C118,7RKV_G,7RKV_L,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycasgytgydyfvrgdyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qpvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklntdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgilvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.","Chain G, C118 Fab Heavy Chain","Chain L, C118 Fab Light Chain",2022-03-14
185,C022,C022,7RKU_J,7RKU_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsvtctvsggsisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhaaayydrsgyyfieyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,diqmtqspstlsasvgdsvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynnyrytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.","Chain J, C022 Antibody Fab Heavy Chain","Chain L, C022 Antibody Fab Light Chain",2022-03-14
189,C118,C118,7RKS_I,7RKS_M,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycasgytgydyfvrgdyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,qpvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklntdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgilvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvapt,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.","Chain I, C118 Antibody Fab Heavy Chain","Chain M, C118 Antibody Fab Light Chain",2022-03-14
191,NCOV617,NCOV617,7E3O_H,7E3O_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgsnkyadsvkgrftisrdnskntlylqmnslraedtavyycarglglrflewpissywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapkllifsnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslkgvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Chen,S.D. et al.; Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV617; Unpublished; 2021.","Chain H, nCoV617 Heigh Chain","Chain L, nCoV617 Light Chain",2022-03-14
192,5-7,5-7,7RW2_I,7RW2_K,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgvinpsggstsyaekfrgrvtmtrdtststvymelsslrsedtavyycardrephsdssgywdslkyyyyyaldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthhhhhhhh,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapelliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlntypftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain; bioRxiv (2021); 2021.","Chain I, 5-7 heavy chain","Chain K, 5-7 light chain",2022-03-14
196,AB1,AB1,7E3C_B,7E3C_C,SARS-CoV-2,Homo sapiens (human),evllvesggglvqpggslrlscaasgltvssnymtwvrqapgkglewvsviysggstfyadsvkgrctisrhnskntlylqmnslraedtavyycardldyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqtgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppltfgggsrveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.","Chain B, Heavy chain of Ab1","Chain C, Light chain of Ab1",2022-03-14
197,AB5,AB5,7E3B_B,7E3B_C,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycardrgyssgwtdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnipftfglgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.","Chain B, Heavy Chain of Ab5","Chain C, Light Chain of Ab5",2022-03-14
198,AB4,AB4,7E39_C,7E39_B,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifssygmhwvrqapgkglewvaviwfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaretvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,niqmtqspsamsasvgdrvtitcrarqgisnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgseteftltisslqpedfatyyclqhnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.","Chain C, Heavy Chain of Ab4","Chain B, Light Chain of Ab4",2022-03-14
199,S2P6,S2P6,7RNJ_H,7RNJ_L,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsqymhwvrqapgqglewigiinpsgvhtsyaqkfqgrvtltrdtststlymelsslrsedtavyycargspkgafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,eivmmqspgtlslspgeratlscrasqsvrsnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Pinto,D. et al.; Broad betacoronavirus neutralization by a stem helix-specific human antibody; Science 373 (6559), 1109-1116 (2021); 2021.","Chain H, Monoclonal antibody S2P6 Fab heavy chain","Chain L, Monoclonal antibody S2P6 Fab light chain",2022-03-14
200,S2X259,S2X259,7RAL_H,7RAL_L,not determined,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggifntytiswvrqapgqglewmgriilmsgmanyaqkiqgrvtitadkststaymeltslrsddtavyycargfngnyygwgdddafdiwgqgtlvtvys,qtvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapkllicgnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpnwvfgggtkltvl,"Tortorici,M.A. et al.; Broad sarbecovirus neutralization by a human monoclonal antibody; Nature 597 (7874), 103-108 (2021); 2021.","Chain H, S2X259 Fab heavy chain","Chain L, S2X259 Fab light chain",2022-03-14
204,C548,C548,7R8O_O,7R8O_P,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarreaygprdyyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsaltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadqgsgsnfvgvfgggtkltvgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","Chain O, C548 Fab Heavy Chain","Chain P, C548 Fab Light Chain",2022-03-14
207,C051,C051,7R8N_O,7R8N_P,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqaggslrlscaasgfgvrnnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntvflqmnslraedtavyycaregdvegfsdlwsgysrdryyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqpasvsgspgqsitfsctgtssdvggynyvswyqqypgkapklliydvtnrpsgvsdrfsgsksgntasltisglqaedeadyycssftssntrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","Chain O, C051 Fab Heavy Chain","Chain P, C051 Fab Light Chain",2022-03-14
210,C032,C032,7R8M_H,7R8M_L,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargvavdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","Chain H, C032 Fab Heavy Chain","Chain L, C032 Fab Light Chain",2022-03-14
212,CR3022,CR3022,7R8L_C,7R8L_D,SARS-CoV-2,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","Chain C, CR3022 Fab heavy chain","Chain D, CR3022 Fab light chain",2022-03-14
213,C099,C099,7R8L_H,7R8L_L,SARS-CoV-2,Homo sapiens (human),vqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfyadsvkgrftisrddskntlflqmnslraedtaiyycardlyssggtdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,eivltqspgtlslspgeratlscrasqsigssylawyqqkpglaprlliygasrratgipdkfsgsgsgadftltisrlepedfavyycqqygsspgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrg,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","Chain H, C099 Fab Heavy Chain","Chain L, C099 Fab Light Chain",2022-03-14
214,C098,C098,7N3I_H,7N3I_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlyssggtdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","Chain H, C098 Fab heavy chain","Chain L, C098 Fab light chain",2022-03-14
215,C032,C032,7N3E_H,7N3E_L,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargvavdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","Chain H, C032 Fab Heavy Chain","Chain L, C032 Fab Light Chain",2022-03-14
216,C099,C099,7N3H_H,7N3H_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfyadsvkgrftisrddskntlflqmnslraedtaiyycardlyssggtdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtlslspgeratlscrasqsigssylawyqqkpglaprlliygasrratgipdkfsgsgsgadftltisrlepedfavyycqqygsspgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","Chain H, C099 Fab Heavy Chain","Chain L, C099 Fab Light Chain",2022-03-14
218,C080,C080,7N3F_H,7N3F_L,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslnisckasgysftiywiawvrqlpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwrslkasdsavyycargvavdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsvltqppsvsgapgqrvtiscagsssnigagfdvywyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqssgsvlsdlyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","Chain H, C080 Fab Heavy Chain","Chain L, C080 Fab Light Chain",2022-03-14
219,G32R7,G32R7,7N64_H,7N64_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgigyadsvkgrftisrdnaknslylqmnslraedtalyycakgrpldrgrswydeiqqgddfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspvslsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tong,P. et al.; Memory B Cell Repertoire for Recognition of Evolving SARS-CoV-2 Spike; Cell(Cambridge,Mass.) (2021); 2021.","Chain H, G32R7 Fab heavy chain","Chain L, G32R7 Fab light chain",2022-03-14
220,C12C9,C12C9,7N62_H,7N62_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssfgmhwvrqapgkglewvavisfdgsnkyyadsvkgrftisrdnskntlylhmnslraedtavyycakdqddgyyyyyymdvwgkgttvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprfliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tong,P. et al.; Memory B Cell Repertoire for Recognition of Evolving SARS-CoV-2 Spike; Cell(Cambridge,Mass.) (2021); 2021.","Chain H, C12C9 Fab heavy chain","Chain L, C12C9 Fab light chain",2022-03-14
221,B1-182.1,B1-182.1,7MM0_H,7MM0_L,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggscfdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgfpdrfsgsgsgtdftltisrlepedfavyycqqygnspwtfgqgtkveirrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants; Science 373 (6556) (2021); 2021.","Chain H, B1-182.1 Fab heavy chain","Chain L, B1-182.1 Fab light chain",2022-03-14
223,A23-58.1,A23-58.1,7LRT_D,7LRT_E,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsnvvcydgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygtspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants; Science 373 (6556) (2021); 2021.","Chain D, antibody A23-58.1 heavy chain","Chain E, antibody A23-58.1 light chain",2022-03-14
227,REGN10985,REGN10985,7M42_D,7M42_C,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Copin,R. et al.; The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies; Cell 184 (15), 3949-3961 (2021); 2021.","Chain D, REGN10985 antibody Fab fragment heavy chain","Chain C, REGN10985 antibody Fab fragment light chain",2022-03-14
228,REGN10989,REGN10989,7M42_B,7M42_A,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Copin,R. et al.; The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies; Cell 184 (15), 3949-3961 (2021); 2021.","Chain B, REGN10989 antibody Fab fragment heavy chain","Chain A, REGN10989 antibody Fab fragment light chain",2022-03-14
229,S2D106,S2D106,7R7N_H,7R7N_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggpfsssaiswvrqapgqglewmggiipmvgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardsrycsggscysvwfdpwgqgtlvtvss,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkvliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvemk,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.","Chain H, S2D106 FAB heavy chain","Chain L, S2D106 FAB light chain",2022-03-14
230,S2E12,S2E12,7R6X_C,7R6X_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.","Chain C, Monoclonal antibody S2E12 Fab heavy chain","Chain D, Monoclonal antibody S2E12 Fab light chain",2022-03-14
231,S309,S309,7R6X_A,7R6X_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.","Chain A, Monoclonal antibody S309 Fab heavy chain","Chain B, Monoclonal antibody S309 Fab light chain",2022-03-14
232,S304,S304,7R6X_H,7R6X_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.","Chain H, Monoclonal antibody S304 Fab heavy chain","Chain L, Monoclonal antibody S304 Fab light chain",2022-03-14
233,S2X35,S2X35,7R6W_H,7R6W_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisaykgntnyaqklqgrvtmttdtststaymelrslrsddtavyycarpdyqvlgydfwigyygmdvwgqgttvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsevvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.","Chain H, Heavy Chain of Fab domain of monoclonal antibody S2X35","Chain L, Light Chain of Fab domain of monoclonal antibody S2X35",2022-03-14
235,S2L20,S2L20,7N8I_H,7N8I_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfnsygmhwvrqapgkglewvafirydggnkyyadsvkgrftisrdnskntlylqmkslraedtavyycanlkdsrysgsyydywgqgtlvtvs,viwmtqspsslsasvgdrvtitcqasqdirfylnwyqqkpgkapkllisdasnmetgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpftfgpgtkvdf,"McCallum,M. et al.; SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern; Science 373 (6555), 648-654 (2021); 2021.","Chain H, S2L20 Fab Heavy Chain Variable Region","Chain L, S2L20 Fab Light Chain Variable Region",2022-03-14
237,S2M11,S2M11,7N8H_M,7N8H_L,SARS-CoV-2,Homo sapiens (human),vqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpissgtsyaqtfqgrvtmtsdtsittaymelsrlrsddtavyycaraapfydfwsgysyfdywgqgtlvtv,ivmmqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssawtfgqgtkv,"McCallum,M. et al.; SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern; Science 373 (6555), 648-654 (2021); 2021.","Chain M, S2M11 Fab Heavy Chain variable region","Chain L, S2M11 Fab Light Chain variable region",2022-03-14
242,COVOX-75,COVOX-75,7ORB_E,7ORB_F,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.","Chain E, COVOX-75 Fab heavy chain","Chain F, COVOX-75 Fab light chain",2022-03-14
243,COVOX-253,COVOX-253,7ORB_C,7ORB_D,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgegatlscrasqsvsssylawyqqkpgqaprlliygassgatgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.","Chain C, COVOX-253 Fab heavy chain","Chain D, COVOX-253 Fab light chain",2022-03-14
250,COVOX-278,COVOX-278,7OR9_H,7OR9_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifirygiswvrqapgqglewmgwisanngytnyaqklqgrvtmttdtststaymelrslrsddtavyycardggiltgyldyfdhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrltitcrasqsiasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqsystlgitfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.","Chain H, COVOX-278 Fab heavy chain","Chain L, COVOX-278 Fab light chain",2022-03-14
251,COVOX-222,COVOX-222,7OR9_A,7OR9_B,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycargegspgnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,dvvmtqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqhydtsprfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.","Chain A, COVOX-222 Fab heavy chain","Chain B, COVOX-222 Fab light chain",2022-03-14
258,2B11,2B11,7E5Y_C,7E5Y_B,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaaseitvssnymnwvrqapgkglewvsviysggttyyadsvkgrftisrdnsentlylqmnslraedtavyycardlmevggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,lpvltqppsasgtpgqrvtiscsgsssnvendnvnwfqqqvpgstpklviyndrlrpsgvpdrfsgsksgtsaylaisglqsedeadyycvawdaslqsyvfgtgtkvtvlrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Pan,Y.B. et al.; Screening of potent and broadly neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries; Unpublished; 2021.","Chain C, 2B11 Fab Heavy chain","Chain B, 2B11 Fab Light chain",2022-03-14
260,368-2,368-2,7E8F_C,7E8F_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesgggvvqpggslrlscaasgfafttyamnwvrqapgrglewvsaisdgggsayyadsvkgrftisrdnskntlylqmnslraedtavyycaktrgrglydyvwgskdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngylyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","Chain C, 368-2 H","Chain B, 368-2 L",2022-03-14
261,N9,N9,7E8F_H,7E8F_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvkpggslrlscaaseftfssysmnwvrqapgkglewvssisssgsqiyyadsvkgrftisrdnakkslylqmnslrvedtavyycatnggahsstwsfygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvspgqtatitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltiggtqamdeaayfcqawdsntgvfgggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","Chain H, N9 H","Chain L, N9 L",2022-03-14
268,BD-515,BD-515,7E88_J,7E88_K,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtgvyycardrglvsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapkllifdashletgvpsrfsasgsgtdftftisslqpediatyychqydnlprtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","Chain J, BD-515 Fab Heavy Chain","Chain K, BD-515 Fab Light Chain",2022-03-14
272,BD-508,BD-508,7E86_A,7E86_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlflqmnslraedtavyycardaqnygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkllifaasslqtgapsrfsgsgsgtdftltisslqpedfatyycqqsystppytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","Chain A, BD-508 Fab Heavy Chain","Chain B, BD-508 Fab Light Chain",2022-03-14
273,BD-623,BD-623,7E7Y_C,7E7Y_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsavysggstyyadsvkgrftisrhnskntlylqmkslrpedtaiyycarlinhyydssgdggafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,ltqpasvsgspgqsitisctgtssdvgsynlvswyqqrpgkapklilyevtkrpsgvsnrfsgsksgntaslaisglqaedeadyyccsyagsstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvap,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","Chain C, BD-623 Fab H","Chain D, BD-623 Fab L",2022-03-14
275,N11,N11,7E7X_M,7E7X_N,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqvvqsgaevkkpgasvkvsckvsgytlieisihwvrqapgkglewmggfdpeagetiyaqkfqgrvtmtedtstdtaymevsslrsedtavyycatgpaiaaaetnwfdlwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,qsaltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiydvtkrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshksyscqvthegstvektvaptecs,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","Chain M, N11 Fab heavy chain","Chain N, N11 Fab Light chain",2022-03-14
277,HB27,HB27,7CYH_E,7CYH_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),vklvesggglvkpggslrlscaasgftftnygmswvrqapgkrlewvaeissggsytyypdtvtgrftisrdnakntlylqmnslraedtavyycarfryggggtvdywgqgtlvtvss,ivltqsptlslspgeratlscrasesvdnygisfmnwfqqkpgqaprlliyaasnqgsgipsrfsgsgsgtdfsltisslepedfavyfcqqskevprifgqgtkveilk,"Wang,X. et al.; Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27; Unpublished; 2021.","Chain E, Heavy chain of HB27","Chain D, Light chain of HB27",2022-03-14
278,B6,B6,7M55_H,7M55_L,SARS-CoV,Mus musculus (house mouse),evqlqqsgpvlvkpgasvrmsckasgytitdyylnwvkqshgkslewlgvlnpysggslysqtfkgkatltvdrssstaylelnsltsedsavyycarqlgrgngldywgqgtsvtvssvstkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,nimmtqspsslavsagekvtmsckssqsvlhssdqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvqaedlavyfchqylssytfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Sauer,M.M. et al.; Structural basis for broad coronavirus neutralization; Nat Struct Mol Biol 28 (6), 478-486 (2021); 2021.","Chain H, B6 antigen binding fragment (Fab) heavy chain","Chain L, B6 antigen binding fragment (Fab) light chain",2022-03-14
282,3D11,3D11,7M7B_H,7M7B_L,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarrwwlrgafdiwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfllyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,nfmltqphsvsaspgktvtipctgssgniasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydnniqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Asarnow,D. et al.; Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia; Cell 184 (12), 3192-3204 (2021); 2021.","Chain H, Antibody Fab 3D11 heavy chain","Chain L, Antibody Fab 3D11 light chain",2022-03-14
283,5A6,5A6,7M71_H,7M71_L,SARS-CoV-2,Homo sapiens (human),qvqlqesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnaknslylqmnslraedtavyycarlitmvrgedywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsslsasvghrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsynlprtfgggtklevlgtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Asarnow,D. et al.; Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia; Cell 184 (12), 3192-3204 (2021); 2021.","Chain H, Antibody 5A6 Fab heavy chain","Chain L, Antibody 5A6 Fab light chain",2022-03-14
286,3D11,3D11,7KQE_I,7KQE_N,not determined,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarrwwlrgafdiwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfllyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,nfmltqphsvsaspgktvtipctgssgniasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydnniqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Goddard,T.D. et al.; UCSF ChimeraX: Meeting modern challenges in visualization and analysis; Protein Sci 27 (1), 14-25 (2018); 2021.","Chain I, Fab 3D11 heavy chain","Chain N, Fab 3D11 light chain",2022-03-14
289,CM25,CM25,7M8J_H,7M8J_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),vqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgpavrrgswfdpwgqgtlvtvss,vvtqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsahwvfgggtkltvl,"Voss,W.N. et al.; Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes; Science 372 (6546), 1108-1112 (2021); 2021.","Chain H, CM25 Fab - Heavy Chain","Chain L, CM25 Fab - Light Chain",2022-03-14
290,47D11,47D11,7AKD_H,7AKD_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsggsisshywswirqppgkglewigyiyysgstnhnpslksrvtisvdtsknqfslklssvtaadtavyycargvllwfgepifeiwgqgtmvtvss,eivmtqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliygastrapgiparfsgsgsgteftltisslqsedfavyycqqynnwpltfgggtkvei,"Fedry,J. et al.; Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11; Sci Adv 7 (23) (2021); 2021.","Chain H, 47D11 neutralizing antibody heavy chain","Chain L, 47D11 neutralizing antibody light chain",2022-03-14
295,CV2-75,CV2-75,7M3I_H,7M3I_L,SARS-CoV-2,Homo sapiens (human),xvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgstnynpslksrvtisvdtsknefslklssvtaadtavyycassqrpdgnlyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,syvltqppsvsvapgqtaritcggnnigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Jennewein,M.F. et al.; Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects; Cell Rep 36 (2), 109353 (2021); 2021.","Chain H, CV2-75 Fab Heavy chain","Chain L, CV2-75 Fab Light chain",2022-03-14
297,47D1,47D1,7MF1_H,7MF1_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvrvsckasggtfstypiswvrqapgqglewmggiipifgtaksaqkfqgrvtitadeftstaymemsslrsedtamyycaregrrygsgwyistgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qlvltqpasvsgspgqsiivsctgtssdvggykfvswyqqhpgkaprvmiydvsnrpsgvsnrfsgsksgntasltisglqaddeadyycssytnsstvvfgggtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhou,X. et al.; Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2; Cell Rep 35 (6), 109109 (2021); 2021.","Chain H, 47D1 Fab heavy chain","Chain L, 47D1 Fab light chain",2022-03-14
298,S2H97,S2H97,7M7W_E,7M7W_F,SARS-CoV-2,Homo sapiens (human),qvrlvqsgaevkksgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistvylqwsslkasdtamyycarqwshytydyyywgqgtlvtissastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsvltqpasvsgspgqsitisctgissdvggynsvswyqqhpgkapklmiydvtnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstppyvfgtgtkvsvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Starr,T.N. et al.; Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape; bioRxiv (2021); 2021.","Chain E, Monoclonal antibody S2H97 Fab heavy chain","Chain F, Monoclonal antibody S2H97 Fab light chain",2022-03-14
299,S2X259,S2X259,7M7W_H,7M7W_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggifntytiswvrqapgqglewmgriilmsgmanyaqkiqgrvtitadkststaymeltslrsddtavyycargfngnyygwgdddafdiwgqgtlvtvysastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qtvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapkllicgnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Starr,T.N. et al.; Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape; bioRxiv (2021); 2021.","Chain H, Monoclonal antibody S2X259 Fab heavy chain","Chain L, Monoclonal antibody S2X259 Fab light chain",2022-03-14
302,BG1-24,BG1-24,7M6I_M,7M6I_N,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriismfgiannaqkfqgrltitadtststaymelsslrsedtavyycargpyyydsggyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsvgsgylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyagsprtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","Chain M, BG1-24 Fab Heavy Chain","Chain N, BG1-24 Fab Light Chain",2022-03-14
304,BG7-20,BG7-20,7M6H_E,7M6H_G,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkagasvkvsckasgytftsydinwvrqasgqglewmgwmnpisgntgyaqkfqgrvtmtrntsittaymelsslrsedtavyfcarggrycssttcysgvgmdvwgqgttvtvpsastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyhqlpgtapkfliygnsnrpsgvpdrfsgsksgtsaslaitrlqaedeadyycqsydsslsgwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","Chain E, BG7-20 Fab Heavy Chain","Chain G, BG7-20 Fab Light Chain",2022-03-14
306,BG7-15,BG7-15,7M6G_R,7M6G_S,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyaiswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtstntaymelrslrsddtaiyycaipyssvtfdcwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsvsgtflawyqqkpgqaprllisgassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","Chain R, BG7-15 Fab Heavy Chain","Chain S, BG7-15 Fab Light Chain",2022-03-14
308,BG1-22,BG1-22,7M6F_H,7M6F_L,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscsvsgftvssnymnwvrqapgkglewvsviypggstfypdsvkgrftisrddskntlylqmnslrpedtaayycassrppigqlvpgldldwfdpwgqgtlvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagyyvhwyqqhpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","Chain H, BG1-22 Fab Heavy Chain","Chain L, BG1-22 Fab Light Chain",2022-03-14
310,BG10-19,BG10-19,7M6E_H,7M6E_L,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgviypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycartqwgynygshffymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsasgtpgqrvtiscsgsssnigsdhvywyqqlpgtapklfiyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsgyvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","Chain H, BG10-19 Fab Heavy Chain","Chain L, BG10-19 Fab Light Chain",2022-03-14
313,BG4-25,BG4-25,7M6D_H,7M6D_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvvrnymtwvrqapgkglewvsviysggttyyadsvkgrftisrdnskntmylqmnslraedtaiyycardlevvgamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygspmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","Chain H, BG4-25 Fab Heavy Chain","Chain L, BG4-25 Fab Light Chain",2022-03-14
314,CR3022,CR3022,7M6D_A,7M6D_B,SARS-CoV-2,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","Chain A, CR3022 Fab Heavy Chain","Chain B, CR3022 Fab Light Chain",2022-03-14
315,2-15,2-15,7L57_H,7L57_L,SARS-CoV-2,Homo sapiens (human),vqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitv,saltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvlg,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.","Chain H, Fab 2-15 variable domain heavy chain","Chain L, Fab 2-15 variable domain light chain",2022-03-14
316,H4,H4,7L58_H,7L58_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvpycsstschrdwyfdlwgrgtlvt,diqmtqsplslpvtpgepasiscrssqslldsddgntyldwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqriefpltfgggtkvei,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.","Chain H, Fab H4 variable domain heavy chain","Chain L, Fab H4 variable domain light chain",2022-03-14
317,2-43,2-43,7L56_J,7L56_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittaymelrrlrsddtavyycarglgvgcsggncyldyyymdvwgkgttvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedegdyycssytssstwvfgggtkltvl,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.","Chain J, Fab 2-43 variable domain heavy chain","Chain L, Fab 2-43 variable domain light chain",2022-03-14
320,2-17,2-17,7LQW_H,7LQW_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggnipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargvgyrgviplnwfdpwgqgtvvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,eivmtqspatlsvspgeratlscrasqsvssdlawyqhkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppftfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.","Chain H, 2-17 Heavy Chain","Chain L, 2-17 Light Chain",2022-03-14
321,5-24,5-24,7L2F_I,7L2F_K,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgltfssyvmhwvrqapgkgldwvgviwydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycardprdyydfwsgydyyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,eivltqspgilslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssgaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.","Chain I, 5-24 heavy chain","Chain K, 5-24 light chain",2022-03-14
324,4-18,4-18,7L2E_I,7L2E_K,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycakdsgynygyswfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,syeltqppsvsvspgqtaritcsadalakqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdnsgtypnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.","Chain I, 4-18 heavy chain","Chain K, 4-18 light chain",2022-03-14
327,1-87,1-87,7L2D_H,7L2D_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgiavigpppstyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.","Chain H, 1-87 heavy chain","Chain L, 1-87 light chain",2022-03-14
328,2-51,2-51,7L2C_C,7L2C_D,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedvetiyaqqfqgrvtmtedtstdtaymelsslrsedtavyycatgwaykstwyfgywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsrmgfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.","Chain C, 2-51 heavy chain","Chain D, 2-51 light chain",2022-03-14
330,4-8,4-8,7LQV_Y,7LQV_Z,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkagssvkvsckasggtfsshtitwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaslqtvdtaiekyygmdvwgqgttvtvss,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Cerutti,G. et al.; Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite; Cell Host Microbe (2021); 2021.","Chain Y, 4-8 Heavy Chain","Chain Z, 4-8 Light chain",2022-03-14
333,NaN,NaN,7CR5_H,7CR5_L,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyimhwvrqapgkglewvavisydgsneayadsvkgrftisrdnskntlylqmsslraedtgvyycaretgdyssswydswgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qlvltqspsasaslgasvkltctlssghsnyaiawhqqqpekgprylmkvnsdgshtkgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgiqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kang,S. et al.; A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation; Nat Commun 12 (1), 2697 (2021); 2021.","Chain H, monoclonal antibody chain H","Chain L, monoclonal antibody chain L",2022-03-14
334,2-7,2-7,7LSS_H,7LSS_L,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahhkierifdywgqgtlvtvss,salaqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssyttsstvfgggtkltvl,"Cerutti,G. et al.; Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies; bioRxiv (2021); 2021.","Chain H, Fab 2-7 variable heavy chain","Chain L, Fab 2-7 variable light chain",2022-03-14
335,1-57,1-57,7LS9_E,7LS9_G,SARS-CoV-2,Homo sapiens (human),evhlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddaknslylqmnslktedtavyycarvhrwaycingvcfgaysdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthhhhhhhh,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspstfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies; bioRxiv (2021); 2021.","Chain E, 1-57 Fab heavy chain","Chain G, 1-57 Fab light chain",2022-03-14
338,DH1041,DH1041,7LAA_H,7LAA_L,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtfssywmswvrqapgkglewvanirqdgsekysvdsvkgrftisrdnaknslylqmnslraedtavyycararradnsgyygfhfdcwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsdsksgtsaslaitrlqaedeadyycqsydsslsgwvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.","Chain H, DH1041 heavy chain","Chain L, DH1041 light chain",2022-03-14
339,DH1052,DH1052,7LAB_H,7LAB_L,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgatvkisckvsgytftdyymhwvqqapgkglewmglvdpedgetiyaekfqgrvtitadtstdtaymelsslrsedtavyycatssgpsrlcgggscyhsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve,ltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqg,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.","Chain H, DH1052 heavy chain","Chain L, DH1052 light chain",2022-03-14
342,DH1047,DH1047,7LD1_H,7LD1_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvqvscqasantftnhyihwvrqapgqglewmgiiyptggntiyaqgfqgrvtmtrdtslntiylelsslrsedtavyycardvrvddswsgydllsggtyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,divmtqspdslavslgeratincrssqsvlyssnnenylawyqqkpgqppklliywastresgipdrfsgsgsgtdftltisrlqaedvavyycqqyyslprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.","Chain H, DH1047 heavy chain","Chain L, DH1047 light chain",2022-03-14
345,DH1050.1,DH1050.1,7LCN_M,7LCN_S,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlpelsmhwvrqapgkglewmggfhpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgspfgvvtdwfdpwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnpyvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.","Chain M, DH1050.1 heavy chain","Chain S, DH1050.1 light chain",2022-03-14
348,CV05-163,CV05-163,7LOP_H,7LOP_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarevmvrgalppygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants; Science 373 (6556), 818-823 (2021); 2021.","Chain H, CV05-163 Fab heavy chain","Chain L, CV05-163 Fab light chain",2022-03-14
352,MW06,MW06,7DPM_J,7DPM_K,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvsvisgsggstyyadsvrgrftisrdnskntlylqmnslraedtavyccakgyyydssgyyfredafdiwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsamsasvgdrvtitcrasqgisnylawfqqkpgkvpkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Jiang,W. et al.; Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV; MAbs 13 (1), 1953683 (2021); 2021.","Chain J, heavy chain of MW06","Chain K, light chain of MW06",2022-03-14
356,15033-7,15033-7,7KML_J,7KML_N,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfdlggysmhwvrqapgkglewvagiyasggatayadsvkgrftisadtskntaylqmnslraedtavyycarsyyyggfgmdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrasqsvssavawyqqkpgkapklliysasdlysgvpsrfsgsrsgtdftltisslqpedfatyycqqshtypitfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.","Chain J, Fab 15033-7 heavy chain","Chain N, Fab 15033-7 light chain",2022-03-14
363,CR3022-B6,CR3022-B6,7KZB_A,7KZB_B,SARS-CoV-2,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,diqmtqspsslsasvgdrvtitcrasqsiysalnwyqqkpgkapklliyaasalqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtdihpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rouet,R. et al.; Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies; MAbs 13 (1), 1922134 (2021); 2021.","Chain A, Fab heavy chain of CR3022-B6 antibody","Chain B, Fab light chain of CR3022-B6 antibody",2022-03-14
364,CR3014-C8,CR3014-C8,7KZB_H,7KZB_L,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycargispfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,diqmtqspsslsasvgdrvtitcrasqyiydslnwyqqkpgkapklliydssylqsgvpsrfsgsgsgtdftltisslqpedfatyycqqswdtpvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rouet,R. et al.; Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies; MAbs 13 (1), 1922134 (2021); 2021.","Chain H, Fab heavy chain of CR3014-C8 antibody","Chain L, Fab light chain of CR3014-C8 antibody",2022-03-14
371,LY-COV481,LY-COV481,7KMI_A,7KMI_B,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycarevagtydywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpggtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.","Chain A, LY-CoV481 Fab heavy chain","Chain B, LY-CoV481 Fab light chain",2022-03-14
372,LY-COV488,LY-COV488,7KMH_A,7KMH_B,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarspyggnswgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.","Chain A, LY-CoV488 Fab heavy chain","Chain B, LY-CoV488 Fab light chain",2022-03-14
373,LY-COV555,LY-COV555,7KMG_D,7KMG_E,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycargyyearhyyyyyamdvwgqgtavtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,diqmtqspsslsasvgdrvtitcrasqsissylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.","Chain D, LY-CoV555 Fab heavy chain","Chain E, LY-CoV555 Fab light chain",2022-03-14
375,2G12,2G12,7L09_M,7L09_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkaggslilscgvsnfrisahtmnwvrrvpggglewvasistsstyrdyadavkgrftvsrddledfvylqmhkmrvedtaiyycarkgsdrlsdndpfdawgpgtvvtvspastkgpsvfplapsxxxxxxxxgtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,dvvmtqspstlsasvgdtititcrasqsietwlawyqqkpgkapklliykastlktgvpsrfsgsgsgteftltisglqfddfatyhcqhyagysatfgqgtrveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Acharya,P. et al.; A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies; bioRxiv (2020); 2020.","Chain M, 2G12 heavy chain","Chain L, 2G12 light chain",2022-03-14
383,NaN,NaN,7B3O_H,7B3O_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrddskntlylqmnslraedtavyycardvadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscaaahhhhhh,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglrspvtksfnrgec,"Bertoglio,F. et al.; A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations; Biorxiv (2020); 2020.","Chain H, Heavy Chain of Fab Fragment","Chain L, Light Chain of Fab Fragment",2022-03-14
384,C1A-C2,C1A-C2,7KFX_H,7KFX_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscavsgftvsnnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsafvgdrvtitcrasegissylawyqqkpgnapklliyaastlesgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.","Chain H, heavy chain of human antibody C1A-C2 Fab","Chain L, light chain of human antibody C1A-C2 Fab",2022-03-14
385,C1A-B3,C1A-B3,7KFW_H,7KFW_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntvflqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.","Chain H, heavy chain of antibody C1A-B3 Fab","Chain L, light chain of antibody C1A-B3 Fab",2022-03-14
388,C1A-F10,C1A-F10,7KFY_H,7KFY_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlengvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.","Chain H, heavy chain of human antibody C1A-F10 Fab","Chain L, light chain of human antibody C1A-F10 Fab",2022-03-14
389,NaN,NaN,7CJF_A,7CJF_B,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsiiysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyycardlqelgsldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcp,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqeansfpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Guo,Y. et al.; A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes; Nat Commun 12 (1), 2623 (2021); 2020.","Chain A, antibody heavy chain","Chain B, antibody light chain",2022-03-14
390,S2A4,S2A4,7JVC_F,7JVC_G,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslflqmnslraedtavyycarvwwlrgsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtc,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","Chain F, S2A4 Fab heavy chain","Chain G, S2A4 Fab light chain",2022-03-14
393,S2H13,S2H13,7JV6_F,7JV6_G,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggdsvqpggslrlscaaagftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycalssgysgyagnywgqgtlvtvss,qavvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgarpedeaeyycllsysgargvfgggtkltvl,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","Chain F, S2H13 Fab heavy chain","Chain G, S2H13 Fab light chain",2022-03-14
396,S304,S304,7JX3_H,7JX3_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diemtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","Chain H, Heavy chain of Fab domain of monoclonal antibody S304","Chain L, Light chain of Fab domain of monoclonal antibody S304",2022-03-14
397,S2H14,S2H14,7JX3_C,7JX3_D,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttgsetyyydssgpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","Chain C, Heavy chain of Fab domain of monoclonal antibody S2H14","Chain D, Light chain of Fab domain of monoclonal antibody S2H14",2022-03-14
398,S309,S309,7JX3_A,7JX3_B,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","Chain A, Heavy chain of Fab domain of monoclonal antibody S309","Chain B, Light chain of Fab domain of monoclonal antibody S309",2022-03-14
399,S304,S304,7JW0_G,7JW0_F,"SARS-CoV-2, Spike protein",Homo sapiens (human),vqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diemtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","Chain G, S304 Fab heavy chain","Chain F, S304 Fab light chain",2022-03-14
402,S2A4,S2A4,7JVA_H,7JVA_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslflqmnslraedtavyycarvwwlrgsfdywgqgtlvtvss,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhvvfgggtkltvl,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","Chain H, S2A4 Fab heavy chain","Chain L, S2A4 Fab light chain",2022-03-14
407,S2X35,S2X35,7JXE_H,7JXE_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisaykgntnyaqklqgrvtmttdtststaymelrslrsddtavyycarpdyqvlgydfwigyygmdvwgqgttvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsevvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell (2020) In press; 2020.","Chain H, S2X35 antigen-binding (Fab) fragment","Chain L, S2X35 antigen-binding (Fab) fragment",2022-03-14
410,S2H14,S2H14,7JXC_H,7JXC_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttgsetyyydssgpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtc,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell (2020) In press; 2020.","Chain H, S2H14 antigen-binding (Fab) fragment","Chain L, S2H14 antigen-binding (Fab) fragment",2022-03-14
411,C121,C121,7K8X_E,7K8X_G,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwispvsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaraplfptgvlagdyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstlvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.","Chain E, C121 Fab Heavy chain","Chain G, C121 Fab Light chain",2022-03-14
413,C144,C144,7K90_O,7K90_P,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvsnnymswvrqapgkglewvsviysggstyyadsvkgrftisrdkskntlylqmnrlraedtavyycaregevegyndfwsgysrdryyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","Chain O, C144 Fab Heavy Chain","Chain P, C144 Fab Light Chain",2022-03-14
416,C135,C135,7K8Z_M,7K8Z_N,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavipfdgrnkyyadsvtgrftisrdnskntlylqmnslraedtavyycasssgylfhsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasvgdrvtitcrasqsisnwlawfqqkpgkapklliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","Chain M, C135 Fab Heavy Chain","Chain N, C135 Fab Light Chain",2022-03-14
419,C119,C119,7K8W_N,7K8W_S,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqklqgrvtmtrdtststvymelsslrsedtavyycaranhettmdtyyyyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspgqsitisctgtssdvggykyvswyqrhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstsvvfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","Chain N, C119 Fab Heavy Chain","Chain S, C119 Fab Light Chain",2022-03-14
421,C110,C110,7K8V_M,7K8V_N,SARS-CoV-2,Homo sapiens (human),qvqlqqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaymqwsslkasdtamyycarsfrddpriavagpadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasvgdrvtitcrasqsisywlawyqqkpgkapklliyqasslesgvpsrfsgsesgteftltisslqpddfatyycqqynsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","Chain M, C110 Fab Heavy Chain","Chain N, C110 Fab Light Chain",2022-03-14
423,C104,C104,7K8U_H,7K8U_L,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlslscavyggslsgyywswirqppgkglewigeinhfgstgynpslksrvtisvdtsksqfsvklssvtaadtavyycarkpllysnlspgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtvslspgeratlscwasqsvsasylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygttprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","Chain H, C104 Fab Heavy Chain","Chain L, C104 Fab Light Chain",2022-03-14
424,C002,C002,7K8T_O,7K8T_P,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakegrpsdivvvvafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","Chain O, C002 Fab Heavy Chain","Chain P, C002 Fab Light Chain",2022-03-14
430,C102,C102,7K8M_A,7K8M_B,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.","Chain A, C102 Fab Heavy Chain","Chain B, C102 Fab Light Chain",2022-03-14
431,C135,C135,7K8R_H,7K8R_L,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavipfdgrnkyyadsvtgrftisrdnskntlylqmnslraedtavyycasssgylfhsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqmtqspstlsasvgdrvtitcrasqsisnwlawfqqkpgkapklliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.","Chain H, C135 Fab Heavy Chain","Chain L, C135 Fab Light Chain",2022-03-14
433,C110,C110,7K8P_H,7K8P_L,SARS-CoV-2,Homo sapiens (human),qvqlqqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaymqwsslkasdtamyycarsfrddpriavagpadafdiwgqgtmvtvssastkgpsvfplapsskstsgptaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasvgdrvtitcrasqsisywlawyqqkpgkapklliyqasslesgvpsrfsgsesgteftltisslqpddfatyycqqynsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","Chain H, C110 Fab Heavy Chain","Chain L, C110 Fab Light Chain",2022-03-14
435,C102,C102,7K8N_A,7K8N_B,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapssksxxxxtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","Chain A, C102 Fab Heavy Chain","Chain B, C102 Fab Light Chain",2022-03-14
436,S2E12,S2E12,7K4N_F,7K4N_G,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvss,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveik,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science 370 (6519), 950-957 (2020); 2020.","Chain F, S2E12 neutralizing antibody Fab fragment (heavy chain)","Chain G, S2E12 neutralizing antibody Fab fragment (light chain)",2022-03-14
440,S2M11,S2M11,7K43_F,7K43_G,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpissgtsyaqtfqgrvtmtsdtsittaymelsrlrsddtavyycaraapfydfwsgysyfdywgqgtlvtvss,eivmmqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssawtfgqgtkveik,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science 370 (6519), 950-957 (2020); 2020.","Chain F, S2M11 Fab fragment (heavy chain)","Chain G, S2M11 Fab fragment (light chain)",2022-03-14
443,S2E12,S2E12,7K3Q_H,7K3Q_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science (2020) In press; 2020.","Chain H, Fab fragment of S2E12 monoclonal antibody, heavy chain","Chain L, Fab fragment of S2E12 monoclonal antibody, light chain",2022-03-14
444,CC12.3,CC12.3,6XC7_C,6XC7_D,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; Structural basis of a public antibody response to SARS-CoV-2; bioRxiv (2020); 2020.","Chain C, CC12.3 heavy chain","Chain D, CC12.3 light chain",2022-03-14
448,CC12.1,CC12.1,6XC2_X,6XC2_Y,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; Structural basis of a public antibody response to SARS-CoV-2; bioRxiv (2020); 2020.","Chain X, CC12.1 heavy chain","Chain Y, CC12.1 light chain",2022-03-14
452,G2,G2,6PXH_H,6PXH_L,MERS-CoV,Mus musculus (house mouse),qvqlqqsggelvkpgasvklscktsgftfsssyiswlkqkpgqslewiawiyagtggteynqkftgkaqvtvdtssstaymqfsslttedsaiyycarggssfamdywgqgtsvtvssasttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgkglevlfq,qlvltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllihtasnqgsgvparfsgsgsgtdfslnihpvedddtamyfcqqseevpltfgagtkleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,N. et al.; Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD; Cell Rep 28 (13), 3395-3405 (2019); 2019.","Chain H, G2 heavy chain","Chain L, G2 light chain",2022-03-14
461,G4,G4,5W9O_H,5W9O_I,MERS-CoV,Mus musculus (house mouse),qvqlqqsgpelvrpgvsvkisckgsgytftdyaihwvkqshakslewigvfstyygntnynqkfkgratmtvdkssstaymelarltsedsaiyycarksyyvdyvdamdywgqgtsvtvssasttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgkglevlfq,divltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllisatsnqgsgvparfigsgsgtdfslnihpveeddtamyfcqqskevprtfgggtkleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Pallesen,J. et al.; Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen; Proc Natl Acad Sci U S A 114 (35), E7348-E7357 (2017); 2017.","Chain H, G4 VH","Chain I, G4 VL",2022-03-14
485,G4,G4,5VZR_A,5VZR_B,MERS-CoV,Mus musculus (house mouse),xvqlqqsgpelvrpgvsvkisckgsgytftdyaihwvkqshakslewigvfstyygntnynqkfkgratmtvdkssstaymelarltsedsaiyycarksyyvdyvdamdywgqgtsvtvssasttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgkglevlfq,divltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllisatsnqgsgvparfigsgsgtdfslnihpveeddtamyfcqqskevprtfgggtkleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Pallesen,J. et al.; Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen; Proc Natl Acad Sci U S A 114 (35), E7348-E7357 (2017); 2017.","Chain A, G4 antibody heavy chain","Chain B, G4 antibody light chain",2022-03-14
487,S3H3,S3H3,7WDF_F,7WDF_G,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),qvqlqqpgaelvrpgasvklsckasgysftrfwmnwvkqrpgqglewigmihpsdsetrlnqkfkdkatltvdkssttaymqlssptsedsavyycarkdydydawfaywgqgtlvtvsaakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,divltqspaslavslgqratiscrasksvsasvysymhwyqqkpgqppklliylasslesgvparfsgsgsgtdftlnihpveeedaatyychhsrelppafgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnr,"Xu,S. et al.; Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein; Emerg Microbes Infect 11 (1), 351-367 (2022); 2022.","Chain F, Heavy chain of S3H3 Fab","Chain G, Light chain of S3H3 Fab",2022-03-14
493,S5D2,S5D2,7WD7_e,7WD7_f,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgqslewigginpniddttynqnfkdkatltvdkssstaymefrsltfddsavyycarddkasfafwgqgtlvtvsaakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,divmsqspsslavsdgervtltckssqsllystnqknylawyqqkpgqspklliywassresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypltfgagtklelradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Xu,S. et al.; Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein; Emerg Microbes Infect 11 (1), 351-367 (2022); 2022.","Chain e, Heavy chain of S5D2 Fab","Chain f, Light chain of S5D2 Fab",2022-03-14
500,R40-1G8,R40-1G8,7SC1_P,7SC1_Q,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymrwvrqapgkglewvsliyaggstfyadsvkgrfiisrhnsknilylqmnslraedtavyfcardlyvfgmdvwgqgtavtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkth,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgrapklliyaastlqsgvpsrfsgsgsgtvftltisslqpedfatyycqqlnsdsstfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe 30 (1), 69-82 (2022); 2022.","Chain P, R40-1G8 Fab heavy chain","Chain Q, R40-1G8 Fab light chain",2022-03-14
503,COVOX-158,COVOX-158,7QNY_H,7QNY_L,not determined,Homo sapiens (human),evqllesggdliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiypggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardlgsgdmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliqaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyrytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.","Chain H, COVOX-158 heavy chain","Chain L, COVOX-158 light chain",2022-03-14
504,COVOX-58,COVOX-58,7QNY_A,7QNY_B,not determined,Homo sapiens (human),qvqlvesggglvqpgrslrlscaasgftfddyamhwvrqppgkglewvsgvswnsgtigyadsvkgrfiisrdnaknslylqmnslkaedtalyycarevggtfgvlisreggldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvapgqtaritcggntigsksvhwyqqrpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdrvvfgggtkltvlgqpkaaptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.","Chain A, COVOX-58 heavy chain","Chain B, COVOX-58 light chain",2022-03-14
505,BETA-55,BETA-55,7QNX_A,7QNX_B,not determined,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsisssryywgwirqppgkglewigtfyysgityynpslksrvtifvdtsknqfslklssvtaadtavyycarprppdyydnsgallfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspstlsasvgdrvtiacrasqsisawlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltinslqpddfatyycqqyissspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.","Chain A, Beta-55 heavy chain","Chain B, Beta-55 light chain",2022-03-14
506,EY6A,EY6A,7QNX_H,7QNX_L,not determined,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfssydmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggklwvyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.","Chain H, EY6A heavy chain","Chain L, EY6A light chain",2022-03-14
509,C1C-A3,C1C-A3,7SN3_H,7SN3_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),mkrglccvlllcgavfvspsasqvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgtntyyadsvkgrftisrdnskntlylqmnslraedtavyycardlayrdyvwryfdlwgrgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,mkrglccvlllcgavfvspsaseivltqspatlslspgeratlscrasqsvstylawyqqkfgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqcrsnwppgitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nabel,K.G. et al.; Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain; Science 375 (6578), eabl6251 (2022); 2021.","Chain H, neutralizing antibody C1C-A3 heavy chain variable region","Chain L, neutralizing antibody C1C-A3 light chain variable region",2022-03-14
514,AB1,AB1,7MJK_H,7MJK_I,"SARS-CoV-2, Spike protein",synthetic construct,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsgqaghhhhhhgdykddddkg,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.","Chain H, Fab ab1 Heavy Chain","Chain I, Fab ab1 Light Chain",2022-03-14
520,CA521,CA521,7E23_B,7E23_C,SARS-CoV-2,Homo sapiens (human),evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigevnhsgstnynpslksrvtisvdtsknqlslklnsvtaadtavyycargntmvrgviipfeywdkgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslg,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Song,D. et al.; Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2; Commun Biol 4 (1), 500 (2021); 2021.","Chain B, CA521 Heavy Chain","Chain C, CA521 Light Chain",2022-03-14
521,P008_056,P008_056,7NTC_H,7NTC_L,SARS-CoV-2,Homo sapiens (human),mgwsciilflvatatgvhsevqlvesggglvkpggslrlscaasgfsfssysmnwvrqapgkglewvssissnsnyiyyadsmkgrftisrdnaknslylqmnslraedtavyycasnrspydssnyyfdywgqgtrvtissastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksgtkhhhhhh,mgwsciilflvatatgvhcairmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqhhdslpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Rosa,A. et al.; SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity; Sci Adv (2021) In press; 2021.","Chain H, P008_056 Fab Heavy chain","Chain L, P008_056 Fab Light chain",2022-03-14
522,S2M28,S2M28,7LY3_F,7LY3_E,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvtviwydgsnryyadsvkgrftisrdnskntlylqmdslraedtavyycaravagewyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,syeltqppsvsvspgqtaritcsgdalakhyaywyrqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsigsswvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvapte,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.","Chain F, S2M28 Fab Heavy Chain","Chain E, S2M28 Fab Light Chain",2022-03-14
524,S2M28,S2M28,7LY2_N,7LY2_O,SARS-CoV-2,Homo sapiens (human),vqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvtviwydgsnryyadsvkgrftisrdnskntlylqmdslraedtavyycaravagewyfdywgqgtlvtvs,yeltqppsvsvspgqtaritcsgdalakhyaywyrqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsigsswvfgggtkltv,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.","Chain N, S2M28 Fab Heavy Chain variable region","Chain O, S2M28 Fab Light Chain variable region",2022-03-14
531,S2L28,S2L28,7LXZ_N,7LXZ_O,SARS-CoV-2,Homo sapiens (human),evqlvesggglvnpggslrlscaasgftfsdytihwvrqapgkglewvssissssnyiyyadsvkgrftisrdnaknslslqmnslraedtavyycardgnaykwllaenvrfdywgqgtlvtvss,vtqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsdrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpnwvfgggtklt,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.","Chain N, S2L28 Fab Heavy Chain variable region","Chain O, S2L28 Fab Light Chain variable region",2022-03-14
537,S2X333,S2X333,7LXY_N,7LXY_O,SARS-CoV-2,Homo sapiens (human),vqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnsknslylqmnslraedtavyfcarafpdssswsgftidywgqgtlvtv,yeltqppsvstaritcggnnierksvhwcqqkpgqapalvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdqvifgggtklt,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.","Chain N, S2X333 Fab Heavy Chain variable region","Chain O, S2X333 Fab Light Chain variable region",2022-03-14
557,DH1043,DH1043,7LJR_S,7LJR_T,SARS-CoV-2,Homo sapiens (human),mgwsciilflvatatgvhsqvqlvqsgaevkkpgssvkvsckasggtfsryainwvrqapgqglewmgriipifgianyaqkfqgkvtitadkststaymelsslrsedtavyycaradyyydssgyffdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvlhealhshytqkslslspgk,mgwsciilflvatatgvhseivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqtprlliygassratgiparfsgsgsgtnftltisrlepedfavyycqqysssrtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.","Chain S, Fab DH1043 heavy chain","Chain T, Fab DH1043 light chain",2022-03-14
558,CR3022,CR3022,6ZH9_HHH,6ZH9_LLL,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),tqmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvastkgpsvfplapssggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Huo,J. et al.; Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2; Nat Struct Mol Biol 27 (9), 846-854 (2020); 2021.","Chain HHH, CR3022 heavy","Chain LLL, CR3022 Light chain",2022-03-14
559,CR3022,CR3022,6ZLR_FFF,6ZLR_GGG,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Nichols,C. et al.; A New Crystal Form of the SARS-CoV-2 Receptor Binding Domain: CR3022 Complex-An Ideal Target for In-Crystal Fragment Screening of the ACE2 Binding Site Surface; Front Pharmacol 11, 615211 (2020); 2021.","Chain FFF, CR3022 FAB HEAVY CHAIN","Chain GGG, CR3022 FAB LIGHT CHAIN",2022-03-14
562,P5A-3C12,P5A-3C12,7D0D_G,7D0D_F,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahslfltvgyssswspfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystphtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain G, Heavy chain of P5A-3C12","Chain F, Light chain of P5A-3C12",2022-03-14
564,P5A-3A1,P5A-3A1,7D0C_G,7D0C_F,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardygdfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain G, Heavy chain of P5A-3A1","Chain F, Light chain of P5A-3A1",2022-03-14
567,COVOX-269,COVOX-269,7NEH_H,7NEH_L,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgltvnrnymswirqapgkglewvsviysggstfyadsvkgrftisrdnskntlslqmnslraedtaiyycardfyegsfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,aiqltqspsflsasigdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfasyycqqlnsypapvfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Supasa,P. et al.; Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera; Cell 184 (8), 2201-2211 (2021); 2021.","Chain H, COVOX-269 Fab heavy chain","Chain L, COVOX-269 fab light chain",2022-03-14
569,COVOX-159,COVOX-159,7NDD_H,7NDD_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsevqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydggnryyadsvkgrftisrdnskntlylqmnrlraedtamyycakdrddgwdwyyfmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspgtlslspgeratlscrasqsisgnylawyqhkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain H, COVOX-159 Fab heavy chain","Chain L, COVOX-159 Fab light chain",2022-03-14
575,COVOX-253H165L,COVOX-253H165L,7NDB_H,7NDB_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygasrrgtgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain H, COVOX-253H165L Fab heavy chain","Chain L, COVOX-253H165L Fab light chain",2022-03-14
576,COVOX-253H55L,COVOX-253H55L,7NDA_H,7NDA_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain H, COVOX-253H55L Fab heavy chain","Chain L, COVOX-253H55L Fab light chain",2022-03-14
578,COVOX-384,COVOX-384,7ND8_H,7ND8_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsevqlvesggglvkpgeslrlscaasgftfsdyymtwirqapgkglewvsyirssghtiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarggvlrflewplnafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynnalgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain H, COVOX-384 Fab heavy chain","Chain L, COVOX-384 Fab light chain",2022-03-14
579,COVOX-316,COVOX-316,7ND7_J,7ND7_K,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqkfqgrvtmtrdtsistaymelsrlrsddtavyscardmafsmvrgsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qavltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnhwvfgggtkltvlgqpkaaptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain J, COVOX-316 Fab heavy chain","Chain K, COVOX-316 Fab light chain",2022-03-14
582,COVOX-158,COVOX-158,7ND6_H,7ND6_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesggdliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiypggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardlgsgdmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliqaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyrytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain H, COVOX-158 Fab heavy chain","Chain L, COVOX-158 Fab light chain",2022-03-14
583,COVOX-150,COVOX-150,7ND5_H,7ND5_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiysggttyyadsvkgrftisrdssmntlylqmnslraedtavyycardlmvygidvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhseivmtqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqldsyppgytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain H, COVOX-150 Fab heavy chain","Chain L, COVOX-150 Fab light chain",2022-03-14
584,COVOX-88,COVOX-88,7ND4_F,7ND4_G,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqlqlqesgpglvkpsqtlsltctvsggsissgsynwtwirqpagkglewigriynsgstnynpslksrvtisvdtsknqlslkvrsvtaadtavyycarhcsggtcypkyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgswaqsaltqppsvseaprqrvtiscsgsssnignnavnwyqqfpgkapklliyyddllpsgvsdrfsgsksgtsaslaisgvqsedeadyycaawddslnvvvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain F, COVOX-88 Fab heavy chain","Chain G, COVOX-88 Fab light chain",2022-03-14
587,COVOX-40,COVOX-40,7ND3_H,7ND3_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvesggglvqpggslrlscavsgftvsrnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlfhrsgyhdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsviwmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapkllifdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpafgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain H, COVOX-40 heavy chain","Chain L, COVOX-40 light chain",2022-03-14
588,S309,S309,7BEP_G,7BEP_I,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain G, S309 heavy chain","Chain I, S309 light chain",2022-03-14
592,COVOX-75,COVOX-75,7BEO_E,7BEO_F,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain E, COVOX-75 heavy chain","Chain F, COVOX-75 light chain",2022-03-14
593,COVOX-253H55L,COVOX-253H55L,7BEO_C,7BEO_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain C, COVOX-253H55L heavy chain","Chain D, COVOX-253H55L light chain",2022-03-14
596,COVOX-75,COVOX-75,7BEN_G,7BEN_I,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain G, COVOX-75 heavy chain","Chain I, COVOX-75 light chain",2022-03-14
597,COVOX-253,COVOX-253,7BEN_D,7BEN_F,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgegatlscrasqsvsssylawyqqkpgqaprlliygassgatgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain D, COVOX-253 heavy chain","Chain F, COVOX-253 light chain",2022-03-14
600,COVOX-269,COVOX-269,7BEM_H,7BEM_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgltvnrnymswirqapgkglewvsviysggstfyadsvkgrftisrdnskntlslqmnslraedtaiyycardfyegsfdiwgqgtmvtvssastggsggggsggggsgg,gasaiqltqspsflsasigdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfasyycqqlnsypapvfgpgtkvdikaaalvprgssawshpqfekggsgggsggsawshpqfek,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain H, COVOX-269 Vh domain","Chain L, COVOX-269 Vl domain",2022-03-14
602,COVOX-45,COVOX-45,7BEL_C,7BEL_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggsyayyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftitslqpediatyycqqydnlpltfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain C, COVOX-45 heavy chain","Chain D, COVOX-45 light chain",2022-03-14
608,COVOX-316,COVOX-316,7BEH_H,7BEH_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqkfqgrvtmtrdtsistaymelsrlrsddtavyscardmafsmvrgsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsqavltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnhwvfgggtkltvlgqpkaaptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","Chain H, COVOX-316 heavy chain","Chain L, COVOX-316 light chain",2022-03-14
609,H014,H014,7CAC_E,7CAC_D,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleilkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsesvteqdskdstyslsstltlskadyekhkvyacevthqglsstksfnrgec,"Lv,Z. et al.; Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody; Science 369 (6510), 1505-1509 (2020); 2021.","Chain E, Heavy chain of H014 Fab","Chain D, Light chain of H014 Fab",2022-03-14
615,H014,H014,7CAH_E,7CAH_D,SARS-CoV-2,Homo sapiens (human),vqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleil,"Lv,Z. et al.; Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody; Science 369 (6510), 1505-1509 (2020); 2020.","Chain E, Heavy chain of H014 Fab","Chain D, Light chain of H014 Fab",2022-03-14
616,S304,S304,7L0N_M,7L0N_N,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Thomson,E.C. et al.; Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity; Cell 184 (5), 1171-1187 (2021); 2021.","Chain M, Monoclonal antibody S304 Fab heavy chain","Chain N, Monoclonal antibody S304 Fab light chain",2022-03-14
620,2-15,2-15,7L5B_H,7L5B_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Biorxiv (2021); 2021.","Chain H, 2-15 Heavy chain","Chain L, 2-15 Light Chain",2022-03-14
621,910-30,910-30,7KS9_H,7KS9_L,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycariygdyawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsrsgtdftftisslqpediatyychqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Banach,B.B. et al.; Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses; bioRxiv (2021); 2021.","Chain H, 910-30 Fab heavy chain","Chain L, 910-30 Fab light chain",2022-03-14
622,LY-COV555,LY-COV555,7L3N_D,7L3N_E,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycargyyearhyyyyyamdvwgqgtavtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhh,diqmtqspsslsasvgdrvtitcrasqsissylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection; bioRxiv (2020); 2021.","Chain D, LY-CoV555 Fab heavy chain","Chain E, LY-CoV555 Fab light chain",2022-03-14
623,P17,P17,7CWL_I,7CWL_K,SARS-CoV,Homo sapiens (human),qqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarhatlmnnkdiwgqgtlvtvssas,gdiqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res 31 (1), 25-36 (2021); 2021.","Chain I, Fab P17 heavy chain","Chain K, Fab P17 light chain",2022-03-14
627,H014,H014,7CWN_O,7CWN_M,SARS-CoV,Homo sapiens (human),vqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvssastkgpsvfplapsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleilkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsesvteqdskdstyslsstltlskadyekhkvyacevthqglsstksfnr,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res (2020) In press; 2020.","Chain O, heavy chain of H014 Fab","Chain M, light chain of H014 Fab",2022-03-14
628,P17,P17,7CWN_G,7CWN_F,SARS-CoV,Homo sapiens (human),qqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarhatlmnnkdiwgqgtlvtvssastkgpsvfplapsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,gdiqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsesvteqdskdstyslsstltlskadyekhkvyacevthqglsstksfnr,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res (2020) In press; 2020.","Chain G, heavy chain of P17 Fab","Chain F, light chain of P17 Fab",2022-03-14
636,CC12.3,CC12.3,7KN7_H,7KN7_L,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","Chain H, CC12.3 Fab heavy chain","Chain L, CC12.3 Fab light chain",2022-03-14
638,NaN,NaN,7CM4_H,7CM4_L,not determined,Homo sapiens (human),qitlkesgptlvkptqtltltcsfsgfslstsgvgvgwirqppgkalewlalidwddnkyhttslktrltiskdtsknqvvltmtnmdpvdtatyycaripgflryrnryyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,elvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggteltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kim,Y.G. et al.; to be publish; Unpublished; 2021.","Chain H, IgG heavy chain","Chain L, IgG light chain",2022-03-14
639,2H2,2H2,7DK7_c,7DK7_d,SARS-CoV-2,Mus musculus (house mouse),qvqlkqsgpslvqpsqslsitctvsgfsltsygvhwvrqspgkglewlgvmwrggntdynaafmsrlsitkdnsksqvffkmnslqtddtaiyycaknggahamdfwgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,nivltqspaslavslgqratiscrasesvdsygnsflhwyqqkpgqppklliylasnlesgvparfsgsgsrtdftltidpveaddaatyycqqnnedpftfgsgtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.","Chain c, The heavy chain fragment of 2H2 Fab","Chain d, The light chain fragment of 2H2 Fab",2022-03-14
648,3C1,3C1,7DD8_A,7DD8_B,SARS-CoV-2,Mus musculus (house mouse),evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcg,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.","Chain A, The heavy chain of 3C1 fab","Chain B, The light chain of 3C1 chain",2022-03-14
651,3C1,3C1,7DCX_E,7DCX_H,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcg,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.","Chain E, The heavy chain of 3C1 fab that binds with the up RBD","Chain H, The light chain of 3C1 fab",2022-03-14
657,CV07-250,CV07-250,6XKQ_H,6XKQ_L,SARS-CoV-2,Homo sapiens (human),qvqlvqseaevkepgasvevsckasgynftnfaiswvrqapgqglewmgwisgyngdtnsaqkflgrvtmttdtstttaymelrslrsddtavyycagsdnygfpyngmdvwgqgttvtvfnqikppsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsaltqppsasgspgqsvtisctgtssdlgayhfvtwyqhypgkapkvmiygvrkrpsgvpdrfsgsksgntasltvsglqdedeadyycssyagnndfvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell(Cambridge,Mass.) (2020); 2020.","Chain H, CV07-250 Heavy Chain","Chain L, CV07-250 Light Chain",2022-03-14
658,CV07-270,CV07-270,6XKP_M,6XKP_N,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymtwirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarargssgwyrigtrwgnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssnvvfgggtmltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell(Cambridge,Mass.) (2020); 2020.","Chain M, CV07-270 Heavy Chain","Chain N, CV07-270 Light Chain",2022-03-14
660,BD-368-2,BD-368-2,7CHH_J,7CHH_K,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpggslrlscaasgfafttyamnwvrqapgrglewvsaisdgggsayyadsvkgrftisrdnskntlylqmnslraedtavyycaktrgrglydyvwgskdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell (2020) In press; 2020.","Chain J, BD-368-2 Fab heavy chain","Chain K, BD-368-2 Fab light chain",2022-03-14
664,BD-604,BD-604,7CHF_H,7CHF_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.","Chain H, BD-604 Fab heavy chain","Chain L, BD-604 Fab light chain",2022-03-14
666,BD-236,BD-236,7CHE_H,7CHE_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstdyadsvkgrftisrdkskntlylqmnslraedtavyycardlgeaggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.","Chain H, BD-236 Fab heavy chain","Chain L, BD-236 Fab light chain",2022-03-14
668,BD-629,BD-629,7CHC_H,7CH5_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlnlqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqgvssflawyqqkpgqaprllihgassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.","Chain H, BD-629 Fab H","Chain L, BD-629 Fab L",2022-03-14
671,2-4,2-4,6XEY_J,6XEY_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqmfqgrvtmtrdtsistaymevsrlrsddtavyycardrswavvyyymdvwgkgttvtvss,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,"Liu,L. et al.; Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike; bioRxiv (2020); 2020.","Chain J, 2-4 Heavy Chain","Chain L, 2-4 Light Chain",2022-03-14
674,4A8,4A8,7C2L_J,7C2L_N,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetmyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatstavagtpdlfdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,eivmtqsplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfpytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Chi,X. et al.; A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2; Science 369 (6504), 650-655 (2020); 2020.","Chain J, heavy chain of 4A8","Chain N, light chain of 4A8",2022-03-14
677,CV30,CV30,6XE1_H,6XE1_L,SARS-CoV-2,Homo sapiens (human),xvqlvesgggliqpggslrlscaasgvivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldvsggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,xivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Hurlburt,N.K. et al.; Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation; bioRxiv (2020); 2020.","Chain H, CV30 Fab Heavy chain","Chain L, CV30 Fab Kappa chain",2022-03-14
678,C105,C105,6XCN_H,6XCN_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargegwelpydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssxlyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqppsasgspgqsvtisctgtssdvggykyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyegsnnfvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies; Cell 182 (4), 828-842 (2020); 2020.","Chain H, C105 Fab Heavy Chain","Chain L, C105 Fab Light Chain",2022-03-14
683,C105,C105,6XCA_H,6XCA_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargegwelpydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqppsgsgspgqsvtisctgtssdvggykyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyegsnnfvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies; Cell 182 (4), 828-842 (2020); 2020.","Chain H, C105 Heavy Chain","Chain L, C105 Light Chain",2022-03-14
684,REGN10987,REGN10987,6XDG_C,6XDG_A,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Hansen,J. et al.; Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail; Science 369 (6506), 1010-1014 (2020); 2020.","Chain C, REGN10987 antibody Fab fragment heavy chain","Chain A, REGN10987 antibody Fab fragment light chain",2022-03-14
685,REGN10933,REGN10933,6XDG_B,6XDG_D,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Hansen,J. et al.; Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail; Science 369 (6506), 1010-1014 (2020); 2020.","Chain B, REGN10933 antibody Fab fragment heavy chain","Chain D, REGN10933 antibody Fab fragment light chain",2022-03-14
686,AB23-FAB-HEAVY,AB23-FAB-LIGHT,7BYR_H,7BYR_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarpqggsswyrdyyygmdvwgqgttvtvss,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,"Cao,Y. et al.; Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells; Cell 182 (1), 73-84 (2020); 2020.","Chain H, Ab23-Fab-Heavy Chain","Chain L, Ab23-Fab-Light Chain",2022-03-14
687,NaN,NaN,7BWJ_H,7BWJ_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslktrvtisvdtsknqfslklssvtaadtavyycaravvgivvvpaagrrafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Ju,B. et al.; Human neutralizing antibodies elicited by SARS-CoV-2 infection; Nature 584 (7819), 115-119 (2020); 2020.","Chain H, antibody heavy chain","Chain L, antibody light chain",2022-03-14
688,CB6,CB6,7C01_C,7C01_D,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsmntlflqmnslraedtavyycarvlpmygdyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkththhhhhh,divmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2; Nature 584 (7819), 120-124 (2020); 2020.","Chain C, CB6 heavy chain","Chain D, CB6 light chain",2022-03-14
690,S309,S309,6WPT_D,6WPT_E,not determined,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveik,"Pinto,D. et al.; Structural and functional analysis of a potent sarbecovirus neutralizing antibody; bioRxiv (2020); 2020.","Chain D, S309 neutralizing antibody heavy chain","Chain E, S309 neutralizing antibody light chain",2022-03-14
695,S309,S309,6WS6_E,6WS6_F,not determined,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Pinto,D. et al.; Structural and functional analysis of a potent sarbecovirus neutralizing antibody; bioRxiv (2020); 2020.","Chain E, S309 antigen-binding (Fab) fragment, heavy chain","Chain F, S309 antigen-binding (Fab) fragment, light chain",2022-03-14
698,B38,B38,7BZ5_H,7BZ5_L,SARS-CoV-2,Homo sapiens (human),gdevqlvesggglvqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycareaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,gddivmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Wu,Y. et al.; A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2; Science 368 (6496), 1274-1278 (2020); 2020.","Chain H, Heavy chain of B38","Chain L, Light chain of B38",2022-03-14
700,7D10,7D10,6J11_F,6J11_G,MERS-CoV,Mus musculus (house mouse),gggsgggsgggsevqlvesgaevvkpgasvkmsckasgypftsynihwikqtpgqglewigaiypgngdtsytqkfkvkatltsdkssstaymqlssltsedsavyfcarygnypsyamdywgqgtsvtvss,divmtqspasltvslgqratiscrasksvsasgynylhwyqqrpgqppklliylafnlesgvparfngsgsgtdftlnihpveeedaatyycqhsrdlpftfgsgtkleik,"Zhou,H. et al.; Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein; Nat Commun 10 (1), 3068 (2019); 2019.","Chain F, VH of 7D10","Chain G, VL of 7D10",2022-03-14
703,CDC2-C2,CDC2-C2,6C6Z_H,6C6Z_L,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsiyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycaregghqgycsggscydfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkglevlfq,dvvmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpafgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J. Virol. 92 (10), e02002-17 (2018); 2018.","Chain H, Antibody CDC2-C2 heavy chain","Chain L, Antibody CDC2-C2 light chain",2022-03-14
705,JC57-14,JC57-14,6C6Y_H,6C6Y_L,SARS-CoV,Macaca mulatta (Rhesus monkey),qvqlqesgpglvkpsetlsltcavsgdsissnywswirqppgkglewigrfsgsggstdfnpslksrvtistdtsknqfslnlrsvtaadtavyycaktysgtfdywgqgvlvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveia,diqmtqspsslsasvgdrvtitcrasqdinnylswyqqkpgkapkpliyyassletgvpsrfsgsrsgtdytltisslqledfatyycqqynnspysfgqgtkveikrtvaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlssteyqshkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J Virol 92 (10), e02002-17 (2018); 2018.","Chain H, JC57-14 Heavy chain","Chain L, JC57-14 Light chain",2022-03-14
707,JC57-14,JC57-14,6C6X_H,6C6X_L,SARS-CoV,Macaca mulatta (Rhesus monkey),qvqlqesgpglvkpsetlsltcavsgdsissnywswirqppgkglewigrfsgsggstdfnpslksrvtistdtsknqfslnlrsvtaadtavyycaktysgtfdywgqgvlvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggsk,diqmtqspsslsasvgdrvtitcrasqdinnylswyqqkpgkapkpliyyassletgvpsrfsgsrsgtdytltisslqledfatyycqqynnspysfgqgtkveikrtvaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlssteyqshkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J Virol 92 (10), e02002-17 (2018); 2018.","Chain H, JC57-14 Heavy chain","Chain L, JC57-14 Light chain",2022-03-14
711,MCA1,MCA1,5GMQ_B,5GMQ_C,SARS-CoV,Homo sapiens (human),atrleesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaskqgdyydrtsyafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkts,dveltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Chen,Z. et al.; Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset; J. Infect. Dis. 215 (12), 1807-1815 (2017); 2017.","Chain B, MCA1 heavy chain","Chain C, MCA1 light chain",2022-03-14
712,4C2,4C2,5DO2_C,5DO2_D,MERS-CoV,Mus musculus (house mouse),dvklvesggglvkpggslklscaasgftfssytmswvrqtpekrlewvatissggsytyypdsvkgrftisrdnakntlylqmsslksedtamyyctrdgndydywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcg,diqmtqttsslsaslgdrvtiscrasqdisnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcqqgntlprtfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Li,Y. et al.; A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein; Cell Res. 25 (11), 1237-1249 (2015); 2015.","Chain C, 4C2 heavy chain","Chain D, 4C2 light chain",2022-03-14
714,H11B11-FAB,H11B11-FAB,7E7E_C,7E7E_D,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfidyymnwvrqapgkglewvgfirnkandytteystsvkgrftisrdnskntlylqmnslraedtavyycarhmyddgfdfwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveshhhhhhhh,diqmtqspsslsasvgdrvtitcrasssvrymhwyqqkpgkapklliydtsklasgvpsrfsgsgsgtdytltisslqpedfatyycqqwsynpltfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Du,Y. et al.; A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants; Nat Commun 12 (1), 5000 (2021); 2021.","Chain C, h11B11-Fab","Chain D, h11B11-Fab",2022-03-14
716,8D3,8D3,7W9F_A,7W9F_B,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgkslewigginpnigdtsynqnfkgkatltvdrssstaymelrsltsedsavyycardgypyyyaldhwgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgckpcictvpevssvfifppkpkdvltitltpkvtcvvvdiskddpevqfswfvddvevhtaqtqpreeqfnstfrsvselpimhqdwlngkefkcrvnsaafpapiektisktkgrpkapqvytipppkeqmakdkvsltcmitdffpeditvewqwngqpaenykntqpimdtdgsyfvysklnvqksnweagntftcsvlheglhnhhtekslshspgk,divmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkaliystsyrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynsypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,Y. et al.; Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies; Nat Commun 13 (1), 871 (2022); 2022.","Chain A, The heavy chain of 8D3","Chain B, The light chain of 8D3",2022-03-14
717,S-E6,S-E6,7KN4_M,7KN4_N,SARS-CoV-2,Homo sapiens (human),qvtlresgpglvkpsetlsltcavsggslssvnyywswirqhpgkglewigyiyysgstnynpslksrvtmsldtsknqfslklssvtaadtavyycatpgaimgalhiwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qavltqpssasstpgqrviiscsgsssnigsntvswyqqvpgaapklliyfdyrrpsgvpdrfsgtrsgtsaslgisglqsedeadyycaawddslsawvfgrgtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Qiang,M. et al.; Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago; Adv Sci (Weinh) 9 (1), e2102181 (2022); 2021.","Chain M, S-E6 Fab heavy chain","Chain N, S-E6 Fab light chain",2022-03-14
719,S-B8,S-B8,7KN3_M,7KN3_N,SARS-CoV-2,Homo sapiens (human),qvqlvqsgggliqpggslrlscaasgftvslshmnwvrqapgkglewvsitygdgnsdyadsvkgrftisrdnskntlylqmnslraedtavyycareyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyslpltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Qiang,M. et al.; Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago; Adv Sci (Weinh) 9 (1), e2102181 (2022); 2021.","Chain M, S-B8 Fab heavy chain","Chain N, S-B8 Fab light chain",2022-03-14
721,RBD-CHAB15,RBD-CHAB15,7EH5_E,7EH5_Q,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqleesgpglvqpsqslsitctvsdfslttygvhwvrqspgkglewlgviwsggstdynaafisrlsiskdnsksqvffkmnslqtndtaiyycarmgdgyyvgamdywgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,diqltqspailsvspgervsfscrasqsigtsihwyqqrtngsprhlikyasesisgipsrfsgsgsgtdftltingvesediadyycqqghnwpltfgagtklelkratvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yang,T.J. et al.; Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function; Nat Struct Mol Biol 28 (9), 731-739 (2021); 2021.","Chain E, RBD-chAb15, heavy chain","Chain Q, RBD-chAb15, light chain",2022-03-14
727,NaN,NaN,UFZ14096,UFZ14097,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgtntyyadsvkgrftisrdnskntlylqmnslraedtavyycardlayrdyvwryfdlwgrgtlvtvss,eivltqspatlslspgeratlscrasqsvstylawyqqkfgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqcrsnwppgitfgqgtrleik,"Nabel,K.G. et al.; Structural basis for continued antibody evasion by the SARS-CoV-2 receptor-binding domain; Science (2022) In press; 2021.","immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-14
728,F26G19,F26G19,3BGF_B,3BGF_C,SARS-CoV,Mus musculus (house mouse),evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiep,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Pak,J.E. et al.; Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain; J. Mol. Biol. 388 (4), 815-823 (2009); 2008.","Chain B, F26G19 Fab","Chain C, F26G19 Fab",2022-03-14
730,DH851.3,DH851.3,7LU9_q,7LU9_r,not determined,Macaca mulatta (Rhesus monkey),qvtlmesgpalvkvtqtlavtctfsgfsirdsgkgvawirqppggalewltsiywddtkyhdtslkprltifrdtsqtqvililtnmapldtatyycgrinngggwkdhidfwgpgllvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgg,altqppsvsksleqsvtisctgtttgnsvswyqchsgtaprlliydvnkrpsgvsdrfsgskshntasltifglqaedeadyycgsygsggsllfgggtrltvlgqpxkasptvtlfppsseelqankatlvclisdfypgvvkvawkadgsavnagvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvapaec,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.","Chain q, DH851.3 heavy chain","Chain r, DH851.3 light chain",2022-03-14
731,DH851.3,DH851.3,7LU9_p,7LU9_o,not determined,Macaca mulatta (Rhesus monkey),qvtlmesgpalvkvtqtlavtctfsgfsirdsgkgvawirqppggalewltsiywddtkyhdtslkprltifrdtsqtqvililtnmapldtatyycgrinngggwkdhidfwgpgllvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrve,altqppsvsksleqsvtisctgtttgnsvswyqchsgtaprlliydvnkrpsgvsdrfsgskshntasltifglqaedeadyycgsygsggsllfgggtrltvlgqpxkasptvtlfppsseelqankatlvclisdfypgvvkvawkadgsavnagvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvap,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.","Chain p, DH851.3 heavy chain","Chain o, DH851.3 light chain",2022-03-14
736,DH898.1,DH898.1,7LUA_i,7LUA_j,not determined,Homo sapiens (human),qdlllqsgaevrepgasvtvscqasnytfpdyyihwvrlvpgqglewlgemkpkvgvtnvskkirdrlfmtadtstdtaymvlsaltpgdtaiyyctrlepdflsgwahwgkgvlvtvspastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrve,eivmtqtplslsvtpgepaslscrssasllhgngntylhwylrkagqspqllifggskrvpgisdrfigsgagtnftlkissveaddvgfyycaqgvafpwtfgqgtkveikravaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgvlktgnsqesvteqdskdntyslsstltlsntdyqshnvyacevthqglsspvtksfnrge,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.","Chain i, DH898.1 heavy chain","Chain j, DH898.1 light chain",2022-03-14
740,DH717.1,DH717.1,6XRJ_H,6XRJ_L,not determined,Homo sapiens (human),qvqlqesgpglvkpsetlsltcavsgvsindgydwtwirqtpgkglewigyvfgrsgnfnlnpslrnrgiiskdtcknqfslnlnsataadtavyfcargmeglfaaynsldvwgrgllvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveikt,altqppsvsgspgqsviisctgtssdigqynsvswyqqhpdkapklviygvtsrpsgvsdrfsgskygdtasltisglqaedeadyycsshadenmalfgggtrltvlgqpkasptvtlfppsseelqankatlvclisdfypgvvkvawkadgsavnagvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvapa,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2020.","Chain H, DH717.1 heavy chain Fab fragment","Chain L, DH717.1 light chain Fab fragment",2022-03-14
744,COV107-23,COV107-23,7LK9_M,7LKA_F,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlgtglfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsyppgtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Tan,T.J. et al.; Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain; bioRxiv (2021); 2021.","Chain M, COV107-23 heavy chain","Chain F, COV107-23 light chain",2022-03-14
748,CR3022,CR3022,7JN5_H,7JN5_L,SARS-CoV-2,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvvsrrlppsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Wu,N.C. et al.; A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody; PLoS Pathog 16 (12), e1009089 (2020); 2020.","Chain H, CR3022 heavy chain","Chain L, CR3022 light chain",2022-03-14
749,1C4,1C4,6XGC_I,6XGC_J,not determined,Macaca fascicularis (crab-eating macaque),evqlvesggglakpggslrlscaasgftfstyamhwvrqapgkglewisginsgggstwytasvkgrftisrdnskstlslqmnslrtedtavyycakdggnaifglvitnygldswgqgavvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggskppthhhhhh,qsvltqppsasgapgqsvtiscsgsssnfgsnhvywyqqlsgkapklliynnnrrpsgvpdrfsgsksgtsaslaisglqsedeadyycsvwdsslnnvlfgggtrltvlgqpkaapsvtlfppsseelqankatlvclisdfypgvvkvawkadgnsvntgvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvapaecs,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.","Chain I, 1C4 Fab heavy chain","Chain J, 1C4 Fab light chain",2022-03-14
752,D12,D12,4ZPV_A,4ZPV_B,MERS-CoV,Mus musculus (house mouse),evklvesggglvkpggslklscaasgftfssyamswvrqtpekrlewvatissggtytyypdsvkgrftisrdnaentlylqmsslrsedtamyycvrdgnsmdywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiepr,diqmtqttsslsaslgdrvtiicrasqdinnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgsdysltisnleqediatyfcqqantlpptfgagtklelrradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,L. et al.; Evaluation of candidate vaccine approaches for MERS-CoV; Nat Commun 6, 7712 (2015); 2015.","Chain A, D12 Fab Heavy chain","Chain B, D12 Fab light chain",2022-03-14
756,M336,M336,4XAK_D,4XAK_E,MERS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtasyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstscnrgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsgqaghhhhhhgdykddddkg,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ying,T. et al.; Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody; Nat Commun 6, 8223 (2015); 2015.","Chain D, Heavy chain of neutralizing antibody m336","Chain E, Light chain of neutralizing antibody m336",2022-03-14
758,1AF10,1AF10,4F2M_C,4F2M_D,SARS-CoV,Mus musculus (house mouse),qvqlqqsgpelvkpgasvkisckasgyafssswmnwvkqrpgqglewigriypgdgetnysekfkgkatltadkssstaymhlssltsvdsavyfcarggyrydpyyamdywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiep,dilltqspailsvspgervslscrasqsigtsihwyqqrtngsprplikyasesisgipsrfsgsgsgtdftlninsvesediadyfcqqtdswpttfgagtklelkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Reguera,J. et al.; Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies; PLoS Pathog. 8 (8), E1002859 (2012); 2012.","Chain C, monoclonal antibody 1AF10, heavy chain","Chain D, monoclonal antibody 1AF10, light chain",2022-03-14
760,CR3022,CR3022,6W7Y_A,6W7Y_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Chen,W.H. et al.; Structure and Antigenicity of the SARS-CoV-2 Receptor Binding Domain; Unpublished; 2020.","Chain A, CR3022 Heavy chain","Chain B, CR3022 Light chain",2022-03-14
762,S/RBD,S/RBD,QOQ45101,QOQ45102,"SARS-CoV-2, Spike protein RBD",synthetic construct,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,W. et al.; Phage display library derived human Fab against SARS-CoV-2 spike protein receptor binding domain; Unpublished; 2020.","anti-SARS-CoV-2 S/RBD immunoglobulin heavy chain, partial [synthetic construct]","anti-SARS-CoV-2 S/RBD immunoglobulin light chain, partial [synthetic construct]",2022-03-14
763,NaN,NaN,BAE94186,BAE94187,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysfanhwiawvrqmpgkglewmgifnpdnsdttyspsfqgqvtfsadksisiaylhwsslkasdtaiyycarlalsdgwlhdfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdktht,eivmtqsplslpvtlgqpasisckssqslvdtngntyliwfhqrpgqsprrliyqvskrdsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgtyrpptlgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,J. et al.; Production of an anti-severe acute respiratory syndrome (SARS) coronavirus human monoclonal antibody Fab fragment by using a combinatorial immunoglobulin gene library derived from patients who recovered from SARS; Clin Vaccine Immunol 13 (5), 594-597 (2006); 2006.","immunoglobulin heavy chain, partial [Homo sapiens]","immunoblobulin light chain, partial [Homo sapiens]",2022-03-14
764,GAMMA-1,NaN,7NP1_K,7NP1_O,SARS-CoV-2,Homo sapiens (human),evqlvqsggglvkpggslrlscaasgitvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargeggsivgvtsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,asdiqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgseteftltisslhpddfatyycqqsystlpytfgqgtkveikrtaaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhklyacevthqglsspvtksfnrgec,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.","Chain K, Immunoglobulin gamma-1 heavy chain","Chain O, Immunoblobulin light chain",2022-03-14
768,NaN,NaN,7BNV_H,7BNV_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhpspyyygsgsysggfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,asdivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqydnwplmhtfgqgtkleikrtaaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhklyacevthqglsspvtksfnrgec,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.","Chain H, Heavy Chain","Chain L, Light Chain",2022-03-14
769,NaN,NaN,7PHG_H,7PHG_L,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqqfqervtitrdmststaymelsslgsedtavyycaapncsggscydgfdlwgqgtmvtvss,eivltqspgtlslspgeratlscrgsqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Fenwick,C. et al.; A highly potent antibody effective against SARS-CoV-2 variants of concern; Cell Rep 37 (2), 109814 (2021); 2021.","Chain H, Heavy ChaIn variable","Chain L, Light ChaIn",2022-03-14
770,NaN,NaN,7RR0_B,7RR0_C,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgnanyaprfqervtitrdmstntaymelsslrsedtavyycaapncsrtlcydgfnmwgqgtmvtv,eivltqspgslslspgeratlscrasqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsetdftltisrlepedfavyycqqydsspwtfgqgtkvei,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","Chain B, PDI 222 Fab Heavy Chain","Chain C, PDI 222 Fab Light Chain",2022-03-14
771,NaN,NaN,7MZN_H,7MZN_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscvasgltvssnymnwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslraedtavyycarvggycssancvsdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapkimiydasiletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtqleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","Chain H, PDI 231 heavy chain","Chain L, PDI 231 light chain",2022-03-14
772,NaN,NaN,7MZM_H,7MZM_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkgpewvsyisggssftnyadsvqgrftiyrdnaknsmflrmnslraedtavyycarspptgdssdwydspaynnyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,eivltqspvtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtsptvtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","Chain H, PDI 215 heavy chain","Chain L, PDI 215 light chain",2022-03-14
773,NaN,NaN,7MZL_H,7MZL_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlqqwgagllkpsetlsltcvvygetlsgyywtwirqspgkglewigeislrgtanynpslksrvtlsveasknqfslkmtsvtaadtavyycvggvvldnvvwfdpwgqgipvtvslastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,esvltqspvslslspgeratlscrasqsvgtylawyqhrpgqaprlliynaskratgiparfsgsgsgtdftltisslepedlavyfcqqrsnwltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","Chain H, PDI 210 heavy chain","Chain L, PDI 210 light chain",2022-03-14
774,NaN,NaN,7MZK_H,7MZK_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),lvqlvqsgaevkkpgasvkisckasgytftsyymhwvrqapgqglewmgiinpsgggtsyaqkfqgrvtmtrdtststvymeltslrsddtavyycakdrvtifwgngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,divmtqspvslavslgeratikckssqsvlyssnnknylgwyqqkpgqplrlliywastresgvpdrfsgsgsgtdftltisslqaedvavyychqysttpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","Chain H, PDI 96 heavy chain","Chain L, PDI 96 light chain",2022-03-14
776,NaN,NaN,7MZK_F,7MZK_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","Chain F, WCSL 129 heavy chain","Chain D, WCSL 129 light chain",2022-03-14
778,NaN,NaN,7MZJ_N,7MZJ_M,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),vvqlvesggglvkpggslrlscaasgftfsyawmswvrqapgkglewvgrikrksdggttdyaapvkgrftisrddskntlylqmsslktedtavyycttdlcrstscehdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtvtcrasqsirsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpaitfgqgtrvqikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","Chain N, PDI 93 heavy chain","Chain M, PDI 93 light chain",2022-03-14
783,NaN,NaN,7MZH_B,7MZH_C,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarsyydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,qsvltqppsvseaprqrvtiscsgsssnighnavhwyqqlpgkapklliyyddllpagvsdrfsgsksgtsaslaisglqsedeadyycaawddilngpvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","Chain B, WCSL 119 heavy chain","Chain C, WCSL 119 light chain",2022-03-14
785,NaN,NaN,7MZG_H,7MZG_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsvfypggstynadsvkgrftisrdnskntlylqmnslraedtavyycardavyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqesystpglftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","Chain H, PDI 42 heavy chain","Chain L, PDI 42 light chain",2022-03-14
786,NaN,NaN,7MZF_H,7MZF_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymswvrqapgkglewvsviysggttyyadsvkgrftisrdsskntlylqmnslraedtavyycardrgdylfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqppsplfasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgseteftltisslqpddfatyycqqynsyfptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","Chain H, PDI 37 heavy chain","Chain L, PDI 37 light chain",2022-03-14
787,NaN,NaN,7COE_B,7COE_C,not determined,Homo sapiens (human),qvqlvqsgaevkrpgssvkvscktsggtfnnnainwvrqapgqglewmggiipffgiakyaqkfqgrvtitadeststaymelsslrsedtavyycardlpressygsgsyythyyamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,eivltqspatlslspgeratlscgasqsvsssylawyqqkpglaprlliydassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Lee,J.Y. et al.; Crystal structure of Receptor binding domain and Fab complex; Unpublished; 2021.","Chain B, Heavy chain","Chain C, Light chain",2022-03-14
789,NaN,NaN,7E8F_D,7E8F_E,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdkskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","Chain D, H","Chain E, L",2022-03-14
790,NaN,NaN,7E8C_O,7E8C_Q,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdkskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscd,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","Chain O, H","Chain Q, L",2022-03-14
793,NaN,NaN,7DZY_O,7DZY_P,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvaninqdggekyyvdsvrgrftisrdnaknslylqmnslraedtavyycardpydlygdyggtfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtdftltisslqsedfalyycqqynnwwrtfgqgtkveinrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.","Chain O, Fab Heavy chain of enhancing antibody 2490","Chain P, Fab light chain of enhancing antibody 2490",2022-03-14
796,NaN,NaN,7DZX_H,7DZX_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvaninqdgsekyyvdsvkgrftisrdnaknslylqvnslraedtavyycardwdydiltgswfgafdiwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.","Chain H, Fab Heavy chain of enhancing antibody","Chain L, Fab light chain of enhancing antibody",2022-03-14
797,NaN,NaN,7KLG_I,7KLG_M,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfdlggysmhwvrqapgkglewvagiyasggatayadsvkgrftisadtskntaylqmnslraedtavyycarsyyyggfgmdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrasqsvssavawyqqkpgkapklliysasdlysgvpsrfsgsrsgtdftltisslqpedfatyycqqsyrypitfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.","Chain I, Fab 15033 heavy chain","Chain M, Fab 15033 light chain",2022-03-14
799,C1A-B12,C1A-B3,7KFV_H,7KFV_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggatyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlisypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.","Chain H, Heavy chain of antibody C1A-B12 Fab","Chain L, light chain of antibody C1A-B3 Fab",2022-03-14
802,NaN,NaN,7K9Z_B,7K9Z_A,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasggtfstygiswvrqapgqglewmgwispnsggtdlaqkfqgrvtmtrdtststvymelsslrsedtavyycasdprddiaggywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rujas,E. et al.; Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers; Biorxiv (2020); 2020.","Chain B, Fab Heavy Chain","Chain A, Fab Light Chain",2022-03-14
803,NaN,NaN,7K9Z_H,7K9Z_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmggiipmfgttnyaqkfqgrvtitadkststaymelsslrsedtavyycardrgdtidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,sdiqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgngfpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rujas,E. et al.; Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers; Biorxiv (2020); 2020.","Chain H, Fab Heavy Chain","Chain L, Fab Light Chain",2022-03-14
804,NaN,NaN,5ZXV_C,5ZXV_D,MERS-CoV,Homo sapiens (human),gvqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyycagndywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,svltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.","Chain C, heavy chain","Chain D, light chain",2022-03-14
806,NaN,NaN,5YY5_C,5YY5_D,MERS-CoV,Homo sapiens (human),gvqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyyctntyywgqgtlvt,ltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqlt,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.","Chain C, Heavy chain","Chain D, Light chain",2022-03-14
807,NaN,NaN,5YY5_H,5YY5_L,MERS-CoV,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyyctntyywgqgtlvtvs,gsqpvltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqltvl,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.","Chain H, Heavy chain","Chain L, Light chain",2022-03-14
808,4-61CHAIN,C2312_LIGHT_IGLV2-14_IGLJ2IGL@,7D03_H,7D03_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsvssgsyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarercyygsgraprcvwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain H, Immunoglobulin heavy variable 4-61,chain H of FabP5A-2G7,Epididymis luminal protein 214","Chain L, IGL c2312_light_IGLV2-14_IGLJ2,IGL@ protein",2022-03-14
809,C642_HEAVY_IGHV3-53_IGHD1-26_IGHJ6CHAIN,C4203_LIGHT_IGKV1-9_IGKJ4UNCHARACTERIZED,7D00_J,7D00_N,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain J, IG c642_heavy_IGHV3-53_IGHD1-26_IGHJ6,chain H of FabP5A-1B8,IGH@ protein","Chain N, IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",2022-03-14
811,1-8IMMUNOGLOBULIN,C168_LIGHT_IGKV4-1_IGKJ4IMMUNOGLOBULIN,7CZZ_J,7CZZ_N,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycaryivvvpaakgfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain J, Immunoglobulin heavy variable 1-8,Immunoglobulin heavy variable 1-8,chain H of P5A-2F11_3B,Epididymis luminal protein 214,Epididymis luminal protein 214","Chain N, IG c168_light_IGKV4-1_IGKJ4,Immunoglobulin kappa constant",2022-03-14
816,4-59CHAIN,C168_LIGHT_IGKV4-1_IGKJ4UNCHARACTERIZED,7CZX_J,7CZX_N,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyisysgstnynpslksrvtisldtsknqfslklssvtaadtavyycasngqyydiltgqppdywyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain J, Immunoglobulin heavy variable 4-59,chain H of P5A-1B9,IGH@ protein","Chain N, IG c168_light_IGKV4-1_IGKJ4,Uncharacterized protein",2022-03-14
821,3-30-3CHAIN,1-33UNCHARACTERIZED,7CZV_J,7CZV_N,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqaitmvqgvigppfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain J, Immunoglobulin heavy variable 3-30-3,chain H of P5A-1B6_3B,Immunoglobulin gamma-1 heavy chain","Chain N, Immunoglobulin kappa variable 1-33,Uncharacterized protein",2022-03-14
824,3-30-3IMMUNOGLOBULIN,1-33IMMUNOGLOBULIN,7CZU_H,7CZU_K,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqaitmvqgvigppfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain H, Immunoglobulin heavy variable 3-30-3,Immunoglobulin heavy variable 3-30-3,Chain H of P5A-1B6_2B,Immunoglobulin gamma-1 heavy chain,Immunoglobulin gamma-1 heavy chain","Chain K, Immunoglobulin kappa variable 1-33,Immunoglobulin kappa variable 1-33,Uncharacterized protein",2022-03-14
826,3-33CHAINH,C689_LIGHT_IGLV5-37_IGLJ3IGL@,7CZT_I,7CZT_M,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarwfhtggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qpvltqppsssaspgesarltctlpsdinvssyniywyqqkpgsppryllyyysdsdkgqgsgvpsrfsgskdasantgillisglqsedeadyycmiwpsnalyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain I, Immunoglobulin heavy variable 3-33,chainH of P5A-2G9,Immunoglobulin gamma-1 heavy chain","Chain M, IG c689_light_IGLV5-37_IGLJ3,IGL@ protein",2022-03-14
828,C542_HEAVY_IGHV3-53_IGHD3-10_IGHJ6IGH@,C4203_LIGHT_IGKV1-9_IGKJ4UNCHARACTERIZED,7CZS_J,7CZS_N,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain J, IG c542_heavy_IGHV3-53_IGHD3-10_IGHJ6,IGH@ protein","Chain N, IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",2022-03-14
831,C542_HEAVY_IGHV3-53_IGHD3-10_IGHJ6IGH@,C4203_LIGHT_IGKV1-9_IGKJ4IGL,7CZR_J,7CZR_N,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain J, IG c542_heavy_IGHV3-53_IGHD3-10_IGHJ6,IGH@ protein","Chain N, IGL c4203_light_IGKV1-9_IGKJ4,IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",2022-03-14
833,C642_HEAVY_IGHV3-53_IGHD1-26_IGHJ6CHAIN,1-33UNCHARACTERIZED,7CZQ_J,7CZQ_N,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaregpksitgtafdiwgqgtivtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnyfnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain J, IG c642_heavy_IGHV3-53_IGHD1-26_IGHJ6,Chain H of P2B-1A10,Immunoglobulin gamma-1 heavy chain","Chain N, Immunoglobulin kappa variable 1-33,Uncharacterized protein",2022-03-14
835,4-59CHAIN,C181_LIGHT_IGLV2-14_IGLJ3IGL@,7CZP_J,7CZP_N,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtskkqfslklssvtaadtavyycarlerdwpldafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapkfmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsnntfafgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","Chain J, Immunoglobulin heavy variable 4-59,Chain H of P2B-1A1,Anti-RhD monoclonal T125 gamma1 heavy chain","Chain N, IG c181_light_IGLV2-14_IGLJ3,IGL@ protein",2022-03-14
837,BD-629,IGK@,7CH5_H,7CHC_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlnlqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqgvssflawyqqkpgqaprllihgassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.","Chain H, BD-629 Fab H","Chain L, IGK@ protein",2022-03-14
838,NaN,NaN,6YOR_B,6YOR_C,"SARS-CoV-2, Spike protein",Homo sapiens (human),tqmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huo,J. et al.; Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike; Cell Host Microbe 28 (3), 445-454 (2020); 2020.","Chain B, IgG H chain","Chain C, IgG L chain",2022-03-14
840,NaN,NaN,6YM0_H,6YM0_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huo,J. et al.; Potent antibody binding to an unexpected highly conserved cryptic epitope of the SARS-CoV-2 Spike; Unpublished; 2020.","Chain H, heavy chain","Chain L, light chain",2022-03-14
843,NaN,NaN,4ZS6_C,4ZS6_D,MERS-CoV,Homo sapiens (human),evqlletggglvkpggslrlscaasgfslsdyymnwirqapgkglewvayissssgytnygdsvkgrftisrdhaknslylqmnslrvedtavyycvrdrddfwsgyykhwglgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,airmtqspsflsasvgdrvtitcrasqdinsflawyqqrpgkapklliygasnletgvpsrfsgggsgtdftltisslqpediatyycqqydklptfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yu,X. et al.; Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27; Sci Rep 5, 13133 (2015); 2015.","Chain C, fab Heavy Chain","Chain D, fab Light Chain",2022-03-14
845,NaN,NaN,2DD8_H,2DD8_L,SARS-CoV,Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvssastkgpsvfplapsskstsggtsalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsplfvhhhhhhgdykddddkg,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvlgqpkanptvtlfppsseefqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.","Chain H, IGG Heavy Chain","Chain L, IGG Light Chain",2022-03-14
848,NaN,NaN,6WZT_G,6WZT_F,not determined,Macaca fascicularis (crab-eating macaque),qvqlqesgpglvkpsetlsltcavsggtfsayywgwirqppgkglewigsisggsgstdyspslksratisrdtsknqfslkltsvtaadtavyycvrkywgdyyanwfdvwgpgvlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggskppt,diqmtqspsslsasvgdtvtitcrasqsisswlawyqqkpgkapklliykasslqggvpsrfsgsgsgsdftltisslqsedfatyycqqysgrpptfgqgtkveikravaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlsstdyqshnvyacevthqglsspvtksfnrgec,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.","Chain G, Cyno antibody heavy chain","Chain F, Cyno antibody light chain",2022-03-14
851,CC40.8,NaN,7SJS_H,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyvmtwarqapgkglewvsaisgtgytyyadsvkgrftvsrdnskntlflqmsslraedtavyycaitmapvvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,NaN,"Zhou,P. et al.; A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection; Sci Transl Med, eabi9215 (2022) In press; 2022.","Chain H, CC40.8 Fab heavy chain",NaN,2022-03-14
852,58G6,NaN,7E3L_D,NaN,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqhlewigwivvgsgntnyaqkfqervtltrdmstrtaymelsslrsedtavyycaapncnsttchdgfdiwgqgtvvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,NaN,"Li,T. et al.; Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants; Nat Commun 12 (1), 6304 (2021); 2021.","Chain D, 58G6 heavy chain",NaN,2022-03-14
855,13G9,NaN,7E3K_H,NaN,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfsgsavqwvrqargqrlewigwivvgsgntnyaqrfqervtitrdmststaymelsslrsedtavyycaapycsstscrdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,NaN,"Li,T. et al.; Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants; Nat Commun 12 (1), 6304 (2021); 2021.","Chain H, 13G9 heavy chain",NaN,2022-03-14
858,LCA60,NaN,6NB4_H,NaN,SARS-CoV,Homo sapiens (human),evqllesggglvkpggslrlsceasgltfsnvwmswvrqapgkglewvgrikrksegattdygapvkgrftlsrddskntvylqmnslkiddtavyycstltrggdvwsssyyfdywgqgalvtvss,NaN,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.","Chain H, LCA60 heavy chain",NaN,2022-03-14
861,S230,NaN,6NB7_H,NaN,SARS-CoV,Homo sapiens (human),qaqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgttvavss,NaN,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.","Chain H, S230 heavy chain",NaN,2022-03-14
866,S230,NaN,6NB8_H,NaN,SARS-CoV,Homo sapiens (human),qaqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgttvavssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.","Chain H, S230 antigen-binding (Fab) fragment, heavy chain",NaN,2022-03-14
867,LCA60,NaN,6NB5_I,NaN,SARS-CoV,Homo sapiens (human),evqllesggglvkpggslrlsceasgltfsnvwmswvrqapgkglewvgrikrksegattdygapvkgrftlsrddskntvylqmnslkiddtavyycstltrggdvwsssyyfdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,NaN,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.","Chain I, LCA60 antigen-binding (Fab) fragment, heavy chain",NaN,2022-03-14
869,ANTI-H5N1,NaN,7W9E_D,NaN,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgkslewigginpnigdtsynqnfkgkatltvdrssstaymelrsltsedsavyycardgypyyyaldhwgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgckpcictvpevssvfifppkpkdvltitltpkvtcvvvdiskddpevqfswfvddvevhtaqtqpreeqfnstfrsvselpimhqdwlngkefkcrvnsaafpapiektisktkgrpkapqvytipppkeqmakdkvsltcmitdffpeditvewqwngqpaenykntqpimdtdgsyfvysklnvqksnweagntftcsvlheglhnhhtekslshspgk,NaN,"Wang,Y. et al.; Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies; Nat Commun 13 (1), 871 (2022); 2022.","Chain D, Anti-H5N1 hemagglutinin monoclonal anitbody H5M9 heavy chain",NaN,2022-03-14
870,COV107-23,NaN,7LKA_E,NaN,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlgtglfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Tan,T.J. et al.; Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain; bioRxiv (2021); 2021.","Chain E, COV107-23 heavy chain",NaN,2022-03-14
874,NaN,NaN,7O7F_H,NaN,not determined,Mus musculus (house mouse),dvqlvesggglvqpggsrklscsasgfafssfgmhwvrqapekglewvayissgsgtiyyadtvkgrftisrddpkntlflqmtslrsedtamyycvrsiyyygsspfdfwgqgttltvssakttppsvyplapgcgdttgssvtlgclvkgyfpesvtvtwnsgslsssvhtfpallqsglytmsssvtvpsstwpsqtvtcsvahpassttvdkkleps,NaN,"Isaikina,P. et al.; Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist; Sci Adv 7 (25) (2021); 2021.","Chain H, Fab antibody fragment heavy chain",NaN,2022-03-14
875,M396-B10,NaN,7KZC_C,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfstysiswvrqapgqglewmggiapshgfanyaqkfqgrvtittdeststaymelsslrsedtavyycardtatggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Langley,D.B. et al.; Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies; Unpublished; 2021.","Chain C, Fab heavy chain of m396-B10 antibody",NaN,2022-03-14
877,ANTI-COV2-RBD,NaN,7KZA_H,NaN,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,NaN,"Langley,D.B. et al.; Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies; Unpublished; 2021.","Chain H, Fab fragment heavy chain of anti-CoV2-RBD antibody variant CR3022-B6",NaN,2022-03-14
878,NaN,COVD21-C8,NaN,7LK9_N,NaN,NaN,NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,NaN,NaN,"Chain N, COVD21-C8 light chain",2022-03-14
882,NaN,NaN,6ZCZ_F,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycaqthyvsyllsdyatwpydywgqgtqvtvssgpggqhhhhhhgaeqkliseedls,NaN,"Zhou,D. et al.; Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient; Nat Struct Mol Biol 27 (10), 950-958 (2020); 2020.","Chain F, Nanobody",NaN,2022-03-14
883,E4,NaN,7VMU_A,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgggliqpggslrlscaasgvtvssnymswvrqapgrglewvsliypggstyyadsvkgrftisrdnsrntlylqmnslraedtavyycardlsekggmdvwgqgttvtvssggggsggggsggggsggggasdivmtqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsyprfgpgtkveik,NaN,"Li,L. et al.; Antibody engineering improves neutralization activity against K417 spike mutant variants of SARS-CoV-2; Unpublished; 2021.","Chain A, scFv E4",NaN,2022-03-14
884,K-874A,NaN,7FG3_D,NaN,SARS-CoV-2,Homo sapiens (human),aevqlvesgggqvetggslrlscqasgstfsdyvmawfrqrpgkerefvatisrnggtttygssvkgrftisrdnakstvylqmnslkpedtavyycyavggdgdswgqgtqvtvssepktpkpqshhhhhh,NaN,"Haga,K. et al.; Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model; Unpublished; 2021.","Chain D, K-874A VHH",NaN,2022-03-14
886,FD20THE,NaN,7CYV_H,NaN,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),gsssqqvqlqqsgaevkkpgssvkvsckasggtfssyafswvrqapgqglewmgriipilgianyaqkfqgrvtitadiststaymalsslrsedtavyycakvevnigmddyyyyygmdvwgqgttvtvssgggsggggsggggssyvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvlsagrageqkliseedlnsavdhhhhhh,NaN,"Li,T. et al.; Structural insight from a neutralizing human scFv in complex with RBD suggest a new site of vulnerability for SARS-CoV-2; Unpublished; 2021.","Chain H, The heavy chain variable region of the scFv FD20,The light chain variable region of the scFv FD20",NaN,2022-03-14
887,RE9F06,NaN,7OLZ_B,NaN,SARS-CoV-2,Vicugna pacos (alpaca),gsqvqlvesggglvqaggslrlscaasgrtfsndalgwfrqaprkerefvaainwnsgtyyadsvkgrftisrdnakntvylqmnslkpedtavyscaaasdyglpredflydywgqgtqvtvssts,NaN,"Guttler,T. et al.; Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies; EMBO J 40 (19), e107985 (2021); 2021.","Chain B, Nanobody Re9F06",NaN,2022-03-14
888,RE5D06,NaN,7OLZ_C,NaN,SARS-CoV-2,Vicugna pacos (alpaca),gsqvqlvesggglvqpggslrlscaasgitldyyaigwfrqapgkeregvsrirssdgstnyadsvkgrftmsrdnakntvylqmnslkpedtavyycaygpltkygsswywpyeydywgqgtqvtvssts,NaN,"Guttler,T. et al.; Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies; EMBO J 40 (19), e107985 (2021); 2021.","Chain C, Nanobody Re5D06",NaN,2022-03-14
889,F2,NaN,7OAY_LLL,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqaggslrlaciasgrtfhsyvmawfrqapgkerefvaaiswsstptyygesvkgrftisrdnakntvylqmnrlkpedtavyfcaadrgesyyytrpteyefwgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.","Chain LLL, F2 nanobody",NaN,2022-03-14
895,H3,NaN,7OAP_FFF,NaN,SARS-CoV-2,Lama glama (llama),maqvqlvesggglvktggslrlscaasgrtfstysmgwfrqapgkerefvagmrwtgsstfysdsvkgrftvsrnnakdtvylhmnslkpedtavyycaittivrayyteyteadfgswgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.","Chain FFF, H3 nanobody",NaN,2022-03-14
896,C1,NaN,7OAP_AAA,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqpggslrlscaasgftndfysiawfrqapgkeregvswlsvsdntptyvdsvkdrftisrhnanntvylqmnmlkpedtaiyycaagrfagrdtwpssydywgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.","Chain AAA, C1 nanobody",NaN,2022-03-14
897,C5,NaN,7OAO_FFF,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.","Chain FFF, C5 nanobody",NaN,2022-03-14
898,NB17,NaN,7N9T_F,NaN,SARS-CoV-2,Lama glama (llama),hvqlvesggglvqaggslrlscaasgsifssnamswyrqapgkqrelvasitsggnadyadsvkgrftisrdkntvypemsslkpadtavyychavgqeasayapraywgqgtqvtvss,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.","Chain F, Nanobody Nb17",NaN,2022-03-14
901,NB36,NaN,7MEJ_B,NaN,SARS-CoV-2,Lama glama (llama),vqlvesggglvqaggsltltcaasgrtfssetmdmgwfrqapgkerefvaadswndgstyyadsvkgrftisrdsakntlylqmnslkpedtavyycaaetysiyekddswgywgqgtqvtvs,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.","Chain B, Nanobody Nb36",NaN,2022-03-14
902,NB21,NaN,7MEJ_A,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqaggslrlscavsglgahrvgwfrrapgkerefvaaiganggntnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeytywgqgtqvtvss,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.","Chain A, Nanobody Nb21",NaN,2022-03-14
903,NB105,NaN,7ME7_B,NaN,SARS-CoV-2,Lama glama (llama),vqlvesggglvqaggslrlscavsgrtfstygmawfrqapgkerdfvatitrsgettlyadsvkgrftisrdnakntvylqmnslkiedtavyycavrrdsswgysrdlfeydywgqgtqvtvs,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.","Chain B, Nanobody Nb105",NaN,2022-03-14
906,SYBODY#68,NaN,7P7A_D,NaN,SARS-CoV-2,synthetic construct,qvqlvesgggsvqaggslrlscaasgsissitylgwfrqapgkeregvaalitvnghtyyadsvkgrftvsldnakntvylqmnslkpedtalyycaaaawgyawplhqddywywgqgtqvtvs,NaN,"Walter,J.D. et al.; Bispecific sybody constructs neutralize SARS-CoV-2 variants of concern and mitigate emergence of drug-resistance; bioRxiv (2020); 2021.","Chain D, sybody#68",NaN,2022-03-14
908,SYBODY#15,NaN,7P79_H,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvknfemewyrkapgkerewvaaiqsggvetyyadsvkgrftisrdnakntvylqmnslkpedtavyycfvyvgrsyigqgtqvtvs,NaN,"Walter,J.D. et al.; Bispecific sybody constructs neutralize SARS-CoV-2 variants of concern and mitigate emergence of drug-resistance; bioRxiv (2020); 2021.","Chain H, sybody#15",NaN,2022-03-14
922,NB34,NaN,7N9E_D,NaN,SARS-CoV-2,Lama glama (llama),masmtggqqmgrdpnsdvqlvesggglvqaggslrlscaasgftfsnyvmywgrqapgkgrewvsgidsdgsdtayassvkgrftisrdnakntlylqmnnlkpedtalyycvkskdpygspwtrsefddywgqgtqvtvssklaaalehhhhhh,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.","Chain D, Nb34 nanobody",NaN,2022-03-14
923,NB95,NaN,7N9C_E,NaN,SARS-CoV-2,Lama glama (llama),masmtggqqmgrdpnsqvqlvesggglvqaggslrlscaasgrtfssysmgwfrqaqgkerefvatingngrdtyytnsvkgrftisrddatntvylqmnslkpedtaiyycaadkdvyygytsfpneyeywgqgtqvtvssklaaalehhhhhh,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.","Chain E, Nanobody NB95",NaN,2022-03-14
925,NB21,NaN,7N9B_F,NaN,SARS-CoV-2,Lama glama (llama),masmtggqqmgrdpnsqvqlvesggglvqaggslrlscavsglgahrvgwfrrapgkerefvaaiganggntnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeytywgqgtqvtvssklaaalehhhhhh,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.","Chain F, NB21 Nanobody",NaN,2022-03-14
928,NB12,NaN,7MY3_D,NaN,SARS-CoV-2,Mus musculus (house mouse),qvkleesgggsvqaggslrlictapglthnncgldwyrrapgkerefvssisadgttsyadsvkgrftiskdkvedtvylqmnslkpedtaiyscktafpyfgnscvldywgqgtsvtvsshhhhhh,NaN,"Xu,J. et al.; Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants; Nature 595 (7866), 278-282 (2021); 2021.","Chain D, Nanobody Nb12",NaN,2022-03-14
931,NB30,NaN,7MY2_D,NaN,SARS-CoV-2,Mus musculus (house mouse),qvqlvesggglvqaggslrlscaasgltfskyamgwfrqapgkerkfvatiswsgdsafyadsvkgrftisrdnarntvylqmnslkpedtavyycaadrgmgygdfmdywgqgtsvtassasgahhhhhh,NaN,"Xu,J. et al.; Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants; Nature 595 (7866), 278-282 (2021); 2021.","Chain D, Nanobody Nb30",NaN,2022-03-14
934,SB45,NaN,7N0H_Z,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvyrdrmawyrqapgkerewvaaiysagqqtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkdvghhyeyydywgqgtqvtvsa,NaN,"Ahmad,J. et al.; Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction; J Biol Chem 297 (4), 101202 (2021); 2021.","Chain Z, Synthetic nanobody (Sb45)",NaN,2022-03-14
939,#68,NaN,7MFU_F,NaN,SARS-CoV-2,synthetic construct,ssqvqlvesgggsvqaggslrlscaasgsissitylgwfrqapgkeregvaalitvnghtyyadsvkgrftvsldnakntvylqmnslkpedtalyycaaaawgyawplhqddywywgqgtqvtvsa,NaN,"Ahmad,J. et al.; Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction; J Biol Chem 297 (4), 101202 (2021); 2021.","Chain F, Synthetic nanobody #68 (Sb68)",NaN,2022-03-14
940,#14,NaN,7MFU_E,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvqaremewyrqapgkerewvaaikstgtytayaysvkgrftisrdnakntvylqmnslkpedtavyycyvyvgssyigqgtqvtvsa,NaN,"Ahmad,J. et al.; Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction; J Biol Chem 297 (4), 101202 (2021); 2021.","Chain E, Synthetic Nanobody #14 (Sb14)",NaN,2022-03-14
943,NaN,NaN,7B14_D,NaN,SARS-CoV-2,Camelus bactrianus (Bactrian camel),qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","Chain D, Nanobody against SARS-CoV-2",NaN,2022-03-14
944,NaN,NaN,7DEU_B,NaN,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmhwvkqshgkslewigginpnngdntynqklkgkatltvhkssstaymelrsltsedsavyycardgypyyyaldywgqgtsvtvssggggsggggsggggsdivmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkpliysassrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynnypwtfgggtkleikaaahhhhhhhh,NaN,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.","Chain B, antibody scFv",NaN,2022-03-14
945,NaN,NaN,7DET_D,NaN,SARS-CoV-2,Mus musculus (house mouse),mkflvnvalvfmvvyisyiyadgsqvqlvqsgaevkkpgasvklsckasgysftsywvnwvrqapgqglewigmihpsdsetrlnqkfkdrvtitvdkststaymelsslrsedtavyycaradgyewyfdvwgrgtlvtvssggggsggggsggggsdivltqspaslavspgqratitcrasesvdsygnsfmhwyqqkpgqppklliyrasnlesgiparfsgsgsgtdftltinpveandvanyycqqsnedpwtfgqgtkveikaaahhhhhhhh,NaN,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.","Chain D, antibody scFv",NaN,2022-03-14
947,NaN,NaN,7DEO_C,NaN,SARS-CoV-2,Homo sapiens (human),gsevqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnrfyadsvkgrftisrdnskstlylqmnslraedtavyycatdppglrfrfdywgqgtlvtvssggggsggggsggggsdivmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpltfgggtkveikgggshhhhhh,NaN,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.","Chain C, antibody scFv",NaN,2022-03-14
949,MR17-SR31,NaN,7D30_A,NaN,"SARS-CoV-2, Spike protein RBD",synthetic construct,gsssqvqlvesggglvqaggslrlscaasgfpvevwrmewyrqapgkeregvaaiesyghgtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkddgqlayhydywgqgtqvtvsggggsggggsggggsggggsggggsggggsgsssqvqlvesggglvqaggslrlscaasgfpvwqgemawyrqapgkerewvaaissmgyktyyadsvkgrftisrdnakntvylqmnslkpedtavyycavmvgfwyagqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Yao,H. et al.; A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2; PLoS Pathog 17 (3), e1009328 (2021); 2021.","Chain A, sybody fusion of MR17-SR31 with a GS linker",NaN,2022-03-14
950,GLAMASARS-COV-2,NaN,7B17_B,NaN,SARS-CoV-2,synthetic construct,qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvssggggsggggsggggsqvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvssggypydvpdyaghhhhhh,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","Chain B, SARS-CoV-2 neutralizing biparatopic nanobody VE,nanobody E from Lama glama,SARS-CoV-2 neutralizing biparatopic nanobody VE,nanobody E from Lama glama",NaN,2022-03-14
951,SB68,NaN,7KLW_C,NaN,SARS-CoV-2,synthetic construct,sssqvqlvesgggsvqaggslrlscaasgsissitylgwfrqapgkeregvaalitvnghtyyadsvkgrftvsldnakntvylqmnslkpedtalyycaaaawgyawplhqddywywgqgtqvtvs,NaN,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.","Chain C, SB68, Synthetic nanobody",NaN,2022-03-14
952,SB45,NaN,7KLW_B,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvyrdrmawyrqapgkerewvaaiysagqqtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkdvghhyeyydywgqgtqvtvs,NaN,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.","Chain B, SB45, Synthetic Nanobody",NaN,2022-03-14
953,SB16,NaN,7KGK_B,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvayktmwwyrqapgkerewvaaiesygikwtryadsvkgrftisrdnakntvylqmnslkpedtavyycivwvgaqyhgqgtqvtvsagra,NaN,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.","Chain B, Sb16, Sybody-16, Synthetic Nanobody",NaN,2022-03-14
955,NaN,NaN,7KSG_F,NaN,SARS-CoV-2,Lama glama (llama),qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvssgglpetgghhhhhh,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","Chain F, Nanobody against SARS-CoV-2 glycoprotein",NaN,2022-03-14
958,FU2,NaN,7NS6_U,NaN,not determined,Vicugna pacos (alpaca),qvqlvesggglvqpggslrlscaasgftlddyaigwfrqapgkeregvsfitssdgstyyvdsvkgrftisrdnakntvylqmnsltpedtaiyycavgpsfsytgstyyrselpwdydywgqgtqvtvssgglpetgghhhhhh,NaN,"Wrapp,D. et al.; Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation; Science 367 (6483), 1260-1263 (2020); 2022.","Chain U, Fu2 nanobody",NaN,2022-03-14
964,FU2,NaN,7NLL_C,NaN,"SARS-CoV-2, Spike protein",Vicugna pacos (alpaca),qvqlvesggglvqpggslrlscaasgftlddyaigwfrqapgkeregvsfitssdgstyyvdsvkgrftisrdnakntvylqmnsltpedtaiyycavgpsfsytgstyyrselpwdydywgqgtqvtvssgglpetgghhhhhh,NaN,"Hanke,L. et al.; A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo; Nat Commun 13 (1), 155 (2022); 2022.","Chain C, Nanobody Fu2",NaN,2022-03-14
966,NM1230,NaN,7B27_DDD,NaN,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvesggglvrpggslrlscvgsgftfsgyamnwyrqapgkalelvagisnagdlthyeepmkgrvaisrandkntvylqmddlkpedtavyrchapgvrvgtgerkdvwgqgaqvtvsseqkliseedlkkkhhhhhh,NaN,"Wagner,T.R. et al.; NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies; EMBO Rep 22 (5), e52325 (2021); 2021.","Chain DDD, neutralizing nanobody NM1230",NaN,2022-03-14
968,NM1226,NaN,7NKT_BBB,NaN,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvesgggsvqpggslrlsclgsgsldyyaigwfrqapgkeregvsciassgdrtiyadsvkgrftisrdygkntvylqmnslkpedtamyycaalqgsyyytgfvaneydywgqgapvtvsseqkliseedlkkkhhhhhh,NaN,"Wagner,T.R. et al.; NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies; EMBO Rep 22 (5), e52325 (2021); 2021.","Chain BBB, neutralizing nanobody NM1226",NaN,2022-03-14
969,NaN,NaN,7LDJ_H,NaN,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),qvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvscisssggntkyadsvkgrftasrdnakntfylqmnslkpedtavyycaaiaatyysgsyyfqcphdgmdywgkgtqvtvssh,NaN,"Pymm,P. et al.; SARS-CoV-2 receptor binding domain in complex with WNb-2; Proc.Natl.Acad.Sci.USA (2021); 2021.","Chain H, Nanobody 2",NaN,2022-03-14
973,NaN,NaN,7B18_I,NaN,"SARS-CoV-2, Spike protein",Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvss,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","Chain I, Nanobody against spike glycoprotein VHH V",NaN,2022-03-14
974,NaN,NaN,7B18_H,NaN,SARS-CoV-2,Lama glama (llama),sqvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","Chain H, Nanobody against SARS-CoV-2 VHH E",NaN,2022-03-14
979,H11-H4,NaN,6ZH9_FFF,NaN,"SARS-CoV-2, Spike protein RBD",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycaqthyvsyllsdyatwpydywgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2; Nat Struct Mol Biol 27 (9), 846-854 (2020); 2021.","Chain FFF, Nanobody H11-H4",NaN,2022-03-14
980,NaN,NaN,7KN7_B,NaN,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssgdsthyvdsvkgrftisrdnakntvylqmnslkpedtavyycaaqsgsyywcgsdwheydyrgqgtqvtvssgglpetgghhhhhh,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","Chain B, VHH W",NaN,2022-03-14
981,NaN,NaN,7KN6_C,NaN,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvssgglpetgghhhhhh,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","Chain C, VHH V",NaN,2022-03-14
982,NaN,NaN,7KN5_F,NaN,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssggsthfadsvkgrftisrdnakntvylqmnslipedtavyycaaqsgsyywcgsdwheyeywgqgtqvtvss,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","Chain F, VHH U",NaN,2022-03-14
986,NB20,NaN,7JVB_D,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqaggslrlscavsgagahrvgwfrrapgkerefvaaigasggmtnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeyiywgqgtqvtvss,NaN,"Xiang,Y. et al.; Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2; Science 370 (6523), 1479-1484 (2020); 2020.","Chain D, Nanobody Nb20",NaN,2022-03-14
988,NaN,NaN,7A25_F,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvesenmhwyrqapgkerewvaaiystggwtlyadsvkgrftisrdnakntvylqmnslkpedtavyycavqvgywyegqgtqvtvs,NaN,"Custodio,T.F. et al.; Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2; BiorXiv (2020); 2020.","Chain F, Sybody 23",NaN,2022-03-14
991,MNB6,NaN,7KKL_F,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvagitrrgsityyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpaspaygdywgqgtqvtvsshhhhhh,NaN,"Schoof,M. et al.; An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike; Science 370 (6523), 1473-1479 (2020); 2020.","Chain F, Synthetic nanobody mNb6",NaN,2022-03-14
994,NB6,NaN,7KKK_F,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqaggslrlscaasgiifgrnamgwyrqapgkerelvagitrrgsityyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpaspapgdywgqgtqvtvss,NaN,"Schoof,M. et al.; An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike; Science 370 (6523), 1473-1479 (2020); 2020.","Chain F, Synthetic nanobody Nb6",NaN,2022-03-14
997,SB23,NaN,7A29_F,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvesenmhwyrqapgkerewvaaiystggwtlyadsvkgrftisrdnakntvylqmnslkpedtavyycavqvgywyegqgtqvtvs,NaN,"Custodio,T.F. et al.; Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2; BiorXiv (2020); 2020.","Chain F, Neutralising sybody (Sb23)",NaN,2022-03-14
1000,TY1,NaN,6ZXN_F,NaN,SARS-CoV-2,Vicugna pacos (alpaca),maqvqlvetggglvqpggslrlscaasgftfssvymnwvrqapgkgpewvsrispnsgnigytdsvkgrftisrdnakntlylqmnnlkpedtalyycaiglnlssssvrgqgtqvtvssgglpetgghhhhhh,NaN,"Hanke,L. et al.; An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction; BioRxiv (2020); 2020.","Chain F, Nanobody Ty1",NaN,2022-03-14
1003,NaN,NaN,6Z43_Z,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycartenvrsllsdyatwpydywgqgtqvtvssgpggqhhhhhhgaeqkliseedls,NaN,"Huo,J. et al.; Structural basis for a potent neutralising single-domain antibody that blocks SARS-CoV-2 binding to its receptor ACE2; Unpublished; 2020.","Chain Z, Nanobody",NaN,2022-03-14
1006,VHH-55,NaN,6WAR_P,NaN,SARS-CoV,Lama glama (llama),qvqlqesgggsvqaggslrlscvasgsifsinamdwyrqapgkqrelvagitsggstnygdfvkgrftisrdnakntvylqmdslkpedtavyycaaevggwgpprpdywghgtqvtvssgslevlfq,NaN,"Wrapp,D. et al.; Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies; Cell 181 (5), 1004-1015 (2020); 2020.","Chain P, nanobody MERS VHH-55",NaN,2022-03-14
1014,MR17-K99Y,NaN,7CAN_A,NaN,"SARS-CoV-2, Spike protein RBD",synthetic construct,gsssqvqlvesggglvqaggslrlscaasgfpvevwrmewyrqapgkeregvaaiesyghgtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvyddgqlayhydywgqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Li,T. et al.; A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection; Nat Commun 12 (1), 4635 (2021); 2020.","Chain A, sybody MR17-K99Y",NaN,2022-03-14
1015,MR17,NaN,7C8W_A,NaN,"SARS-CoV-2, Spike protein RBD",synthetic construct,qvqlvesggglvqaggslrlscaasgfpvevwrmewyrqapgkeregvaaiesyghgtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkddgqlayhydywgqgtqvtvsag,NaN,"Li,T. et al.; A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection; Nat Commun 12 (1), 4635 (2021); 2020.","Chain A, Synthetic nanobody MR17",NaN,2022-03-14
1016,SR4,NaN,7C8V_A,NaN,"SARS-CoV-2, Spike protein RBD",synthetic construct,gsssqvqlvesggglvqaggslrlscaasgfpvyswnmwwyrqapgkerewvaaieshgdstryadsvkgrftisrdnakntvylqmnslkpedtavyycyvwvghtyygqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Li,T. et al.; A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection; Nat Commun 12 (1), 4635 (2021); 2020.","Chain A, Synthetic nanobody SR4",NaN,2022-03-14
1017,NaN,NaN,7KM5_D,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqpggslrlscaasgftfknadmnwyrqvpgqglewvtsiysdgrtvyadsvkgrftvsrdnpkstvslqmnslkpedtgvyycmagsksgheldhwgqgtqvtvsshhhhhh,NaN,"Ye,G. et al.; The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates; Elife 10, e64815 (2021); 2021.","Chain D, nanobody",NaN,2022-03-14
1019,80R,NaN,2GHW_D,NaN,SARS-CoV,Homo sapiens (human),maevqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvssggggsggggsggggsettltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevksglvpr,NaN,"Hwang,W.C. et al.; Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R; J. Biol. Chem. 281 (45), 34610-34616 (2006); 2006.","Chain D, anti-sars scFv antibody, 80R",NaN,2022-03-14
1021,N0,NaN,7R9D_N,NaN,not determined,Vicugna pacos (alpaca),qvqlveygggsvqaggylrlscvasgsislssgmgwyrqapgkerelvasisggsstnyadsvkgrftisrdnakntvylqmnslkpedtavyycaaseqltsghaywgqgtqvtvsslehhh,NaN,"Wu,X. et al.; Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies); Proc Natl Acad Sci U S A 118 (41) (2021); 2021.","Chain N, Nanobody N0",NaN,2022-03-14
1022,#16,NaN,7MFV_B,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvayktmwwyrqapgkerewvaaiesygikwtryadsvkgrftisrdnakntvylqmnslkpedtavyycivwvgaqyhgqgtqvtvsa,NaN,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.","Chain B, Synthetic Nanobody #16 (Sb16)",NaN,2022-03-14
1023,RE5D06,NaN,7ON5_A,NaN,SARS-CoV-2,Vicugna pacos (alpaca),egsqvqlvesggglvqpggslrlscaasgitldyyaigwfrqapgkeregvsrirssdgstnyadsvkgrftmsrdnakntvylqmnslkpedtavyycaygpltkygsswywpyeydywgqgtqvtvss,NaN,"Guttler,T. et al.; Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies; EMBO J 40 (19), e107985 (2021); 2021.","Chain A, Nanobody Re5D06",NaN,2022-03-14
1024,NaN,NaN,QZW25479,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqaggslrlscavsgagahrvgwfrrapgkerefvaaigasggmtnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeyiywgqgtqvtvss,NaN,"Zhang,J. et al.; Recombinant expression of a SARS-CoV-2 neutralizing nanobody in Trichoderma reesei; Unpublished; 2021.","anti-SARS-CoV-2 spike protein receptor-binding domain nanobody, partial [synthetic construct]",NaN,2022-03-14
1025,RBD-SPECIFIC,NaN,QYF06674,NaN,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),qlqlvesggglvqaggslrlscaasertfsggvmgwfrqrpgkerefvaairwngastfyadsvkgrftcsrdnakntgylqmnsltpedtavyycaravrtyassdyyfqertydywgqgtqvtvss,NaN,Ma H et al.; Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain; J Virol (2021) In press; 2021.,"anti-SARS-CoV-2 RBD-specific nanobody, partial [Vicugna pacos]",NaN,2022-03-14
1026,RBD-SPECIFIC,NaN,QYF06673,NaN,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),qvqlvesggglvqpggtlrlscaasgftldyyaigwfrqapgkeregvscisgsggitnytdsvkgrftisrdnakntvylqmnslkpedtavyycapvshtvvagcafeawtdfgswgqgtqvtvss,NaN,Ma H et al.; Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain; J Virol (2021) In press; 2021.,"anti-SARS-CoV-2 RBD-specific nanobody, partial [Vicugna pacos]",NaN,2022-03-14
1027,RBD-SPECIFIC,NaN,QYF06672,NaN,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),qvqlvesggglvqaggslrlscaasgrtytmgwfrqapgkerefvaamrwsdtdyadslkgrftisrdnannamylqmnslgpedtavyycaageawlarsthhydywgqgtqvtvss,NaN,Ma H et al.; Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain; J Virol (2021) In press; 2021.,"anti-SARS-CoV-2 RBD-specific nanobody, partial [Vicugna pacos]",NaN,2022-03-14
1028,SB16,NaN,7KGL_B,NaN,"SARS-CoV-2, Spike protein RBD",synthetic construct,qvqlvesggglvqaggslrlscaasgfpvayktmwwyrqapgkerewvaaiesygikwtryadsvkgrftisrdnakntvylqmnslkpedtavyycivwvgaqyhgqgtqvtvsa,NaN,"Ahmad,J. et al.; Crystal structure of synthetic nanobody complexes with SARS-CoV-2 receptor binding domain; Unpublished; 2021.","Chain B, SB16, Sybody-16, Synthetic Nanobody",NaN,2022-03-14
1031,VHH-72,NaN,6WAQ_C,NaN,SARS-CoV,Lama glama (llama),qvqlqesggglvqaggslrlscaasgrtfseyamgwfrqapgkerefvatiswsggstyytdsvkgrftisrdnakntvylqmnslkpddtavyycaaaglgtvvsewdydydywgqgtqvtvssgs,NaN,"Wrapp,D. et al.; Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies; Cell 181 (5), 1004-1015 (2020); 2020.","Chain C, nanobody SARS VHH-72",NaN,2022-03-14
1033,SDAB-5F8,NaN,QNA42481,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqpggslrlscaasgrqavvfgwfrqapgkgleavaaihvpaknryyadsvkgrftisrdnskntlylqmnslraedtavyycaahyefndfvwqgyssdywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.","anti-SARS-CoV-2 nanobody sdAb-5F8, partial [synthetic construct]",NaN,2022-03-14
1034,SDAB-4D8,NaN,QNA42480,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqpggslrlscaasgnidstryhgwfrqapgkgleavaaikgvwpedyyadsvkgrftisrdnskntlylqmnslraedtavyycaadqyewwvpgevgpylywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.","anti-SARS-CoV-2 nanobody sdAb-4D8, partial [synthetic construct]",NaN,2022-03-14
1035,SDAB-3F11,NaN,QNA42479,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqpggslrlscaasggnaaermagwfrqapgkgleavaaiyyakfgpyyadsvkgrftisrdnskntlylqmnslraedtavyycaaeafvqspysgshttkywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.","anti-SARS-CoV-2 nanobody sdAb-3F11, partial [synthetic construct]",NaN,2022-03-14
1036,SDAB-2F2,NaN,QNA42478,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqpggslrlscaasglaqskwaygwfrqapgkgleavaaidvatgpwyyadsvkgrftisrdnskntlylqmnslraedtavyycaahhiptkhpafpdfrdywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.","anti-SARS-CoV-2 nanobody sdAb-2F2, partial [synthetic construct]",NaN,2022-03-14
1037,SDAB-1E2,NaN,QNA42477,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqpggslrlscaasgadafviiggwfrqapgkgleavaaiawtdqheyyadsvkgrftisrdnskntlylqmnslraedtavyycaaqdsayikskgsrayeywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.","anti-SARS-CoV-2 nanobody sdAb-1E2, partial [synthetic construct]",NaN,2022-03-14
